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Abstract 
The N-methyl-D-aspartate receptors (NMDARs) and its interacting proteins constitute 
large macro-molecular complexes (NMDAR complexes) at glutamate synapses. Recent 
human genomic studies discovered many mutations in the genes encoding the 
components of NMDAR complexes in various neurodevelopmental disorders. However, 
little is known about how mutations in these genes alter molecular and cellular 
pathways leading to pathological phenotypes. To answer the question, our lab has been 
systematically mutating synaptic genes in mice using conventional gene targeting 
methods. To further accelerate generation of mutants we adopted the CRISPR/Cas9 
genome editing system in mouse embryonic stem (ES) cells.  
 
SH3 and multiple ankyrin repeat domains 3 (SHANK3) is a crucial scaffolding protein of 
NMDAR complexes and is implicated in autism spectrum disorders, intellectual 
disability, and schizophrenia. A CRISPR/Cas9-induced knockout mutation of SHANK3 
was successfully introduced in ES cells, and these cells were injected into mouse 
blastocysts and three chimaeras were born. These chimaeras were then crossed with 
wild-type mice and germline transmission was confirmed.  
 
Having established a knockout mutation using the CRISPR/Cas9 system, we moved on 
to modify Synaptic GTPase-activating protein 1 (SYNGAP1), another component of 
NMDAR complexes. De novo mutations of SYNGAP1 have been found in intellectual 
disability, autism spectrum disorders, and schizophrenia. To introduce a defined 
mutation in the SYNGAP1 gene, we designed a CRISPR/Cas9-mediated point mutation, 
and ES cell lines with the precise mutation were obtained. These cell lines were further 
developed to create a novel animal colony.  
 
Here we demonstrate CRISPR/Cas9 facilitates disruption of SHANK3, as well as the 
precise editing in SYNGAP1 in mouse ES cells with high efficiency. Furthermore, we 
report successful generation and characterisation of genome-engineered mice using 
CRISPR/Cas9-modified ES cells. 
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Lay summary 
Recent human genomic studies have identified several hundred gene mutations which 
result in neurodevelopmental disorders, including intellectual disability and autism 
spectrum disorders. Many of these genes encode proteins which are located in brain 
synapses. However, little is known about how the mutations in these synaptic genes 
lead to cognitive and behavioural deficits observed in the disorders.  
Genetically modified mice are a strong tool to investigate the functions of such genes 
implicated in human diseases. Therefore, our lab has been systematically mutating 
synaptic genes in mice using conventional gene targeting methods. However, generation 
of mutant mice using this methodology is time-consuming, expensive, and laborious. To 
accelerate generation of mutant mice, we adopted a recently developed gene editing 
technology known as the CRISPR/Cas9 system.   
Here we report rapid generation of genome-engineered mice using the CRISPR/Cas9 
system in mouse embryonic stem (ES) cells. The CRISPR/Cas9 system facilitated 
deletion in an autism-associated gene SHANK3, as well as a precise gene editing in an 
intellectual disability-related gene SYNGAP1 in mouse ES cells with high efficiency. 
Using the modified ES cells, we successfully generated novel mouse models of 
neurodevelopmental disorders. Analysing these mutant mice will elucidate the 
structural and functional roles of these synaptic genes, and further our understanding of 
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1.1 NMDAR complexes  
The N-methyl-D-aspartate receptor (NMDAR) is a glutamate-gated ion channel 
at the excitatory synapses in the central nervous system. NMDAR is one of three 
subtypes of ionotropic glutamate receptors, the others being the α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor and the kainite 
receptor (Fan et al. 2014; Clements & Westbrook 1991; Furukawa et al. 2005). 
When activated by glutamate and glycine (or D-serine), NMDARs  mediate the 
flow of sodium (Na+) and calcium (Ca2+) into the cell, and potassium ions (K+) 
out of the cell (Furukawa et al., 2005). Each NMDAR is a heterotetramer 
composed of two obligatory GluN1 and two modulatory GluN2 (A-D) or GluN3 
(A-B) subunits (Ulbrich & Isacoff 2008; Collingridge et al. 2009). GluN2 subunit 
contains the evolutionarily divergent C-terminal domain which differentially 
interacts with other synaptic proteins (Ryan et al. 2008). NMDARs are critically 
involved in a variety of cellular processes and activity-dependent brain 
functions such as cortical circuit refinement, synaptic plasticity and cognitive 
functions (Akashi et al. 2009; O’Connor et al. 2014; Fan et al. 2014).  
 
The functional diversity of NMDARs may be ascribed to its organisation at the 
postsynaptic density (PSD) (Fan et al. 2014). NMDARs bind more than 70 
synaptic proteins forming macromolecular signalling complexes (Naisbitt et al. 
1999; Husi et al. 2000; Grant & O’Dell 2001; Frank et al. 2016; Fernández et al. 
2009). The C-terminal domain of Glu2B, in particular, plays a key role in the 
formation of ~1.5 MDa NMDAR complexes (Frank et al. 2016). The assembly of 
NMDARs with different synaptic proteins provides a means to modulate the 
receptor properties and trafficking, and links the receptor activation to various 
intracellular signalling pathways (Fan et al. 2014).  
 
Human genomic studies have identified several hundred mutations in the genes 
encoding the components of NMDAR complexes in various neurodevelopmental 
disorders including autism spectrum disorders (ASD) (Durand et al. 2011; 
Berryer et al. 2013; De Rubeis et al. 2014; Lee et al. 2015), intellectual disability 
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(Hamdan et al., 2009; Hamdan et al  2011; Rauch et al., 2012; Mignot et al., 
2016) and schizophrenia (Gauthier et al., 2009; Purcell et al., 2014). Therefore, 
investigating protein interactions in NMDAR complexes will not only give 
insight into molecular mechanisms of NMDAR signalling, but also how its 
dysfunction relates to the pathophysiology of the neurodevelopmental 
disorders. 
 
We focus our attention on two NMDAR-interacting proteins, SHANK3 (SH3 and 
multiple ankyrin repeat domains 3) and SYNGAP1 (Synaptic GTPase-activating 
protein 1) (Figure 1.1). We decided to study SHANK3 and SYNGAP1 together 
because of the following common features. First, haploinsufficiency in SHANK3 
and SYNGAP1 is linked to the same set of brain disorders, including ASD 
(Durand et al. 2011; Berryer et al. 2013; De Rubeis et al. 2014; Lee et al. 2015), 
intellectual disability (Prasad et al., 2001; Hamdan et al., 2009; Hamdan et al  
2011; Rauch et al., 2012; Mignot et al., 2016), schizophrenia (Purcell et al. 2014; 
Gauthier et al. 2009) and epilepsy (Leblond et al. 2014; Berryer et al. 2013). 
Secondly, loss-of-function mouse models of these proteins have overlapping 
phenotypes such as seizures, spatial memory deficits and increased stereotyped 
behaviours (Peça et al. 2011; Kozol et al. 2015; Komiyama et al. 2002; Clement 
et al. 2012). Thirdly, both proteins are enriched at the PSD, and physically 
interact with each other through common binding partners such as the 
membrane-associated guanylate kinases (MAGUKs) (Naisbitt et al. 1999; Sakai 
et al. 2011) (Figure 1.1). Lastly, the C-terminal domain of GluN2B subunit plays 
a crucial role in these interactions (Kim et al. 2005). Considering these 
commonalities, we hypothesised these proteins form a multiprotein complex at 
the PSD and are involved in a common molecular pathway conferring the 
convergent clinical phenotypes. To test our hypothesis, we aimed to create 
novel mouse models carrying mutations in SHANK3 or SYNGAP1 using a 
recently developed genome engineering technology, the CRISPR/Cas9 system in 





Figure 1.1 | NMDAR and its interacting proteins. 
GluN2B subunit of NMDARs has a long cytoplasmic tail involved in protein-protein 
interactions. SYNGAP1 associates with NMDAR via MAGUK (membrane-associated 
guanylate kinase) proteins, while SHANK3 binds to GKAP (guanylate kinase-
associating protein) which in turn associates with MAGUK. Gene mutations in the 
proteins illustrated here (GluN1, GluN2B, MAGUK, GKAP, SYNGAP1 and SHANK3) 
are all implicated in autism spectrum disorder (ASD) and/or intellectual disability, 















SHANK3 is a synaptic scaffolding protein, which physically interacts with 
NMDAR complexes in vitro (Naisbitt et al. 1999). SHANK3 is a member of the 
SHANK family, which connects membrane receptors and other synaptic proteins 
to actin cytoskeleton and G-protein-coupled signalling pathways (Boeckers et al. 
1999; Naisbitt et al. 1999). As shown in Figure 1.1, SHANK3 interacts with 
NMDARs via MAGUKs and guanylate kinase-associating protein (GKAP) 
(Naisbitt et al. 1999; O’Connor et al. 2014).   
 
The SHANK3 gene is located on mouse chromosome 15 (22q13.3 in human), 
and has 22 exons (Figure 1.2). SHANK3 has a wide range of mRNA splice 
variants resulting from combinations of six intragenic promoters (Monteiro & 
Feng 2017) and several alternative splicing exons (Wang et al. 2014; Zhu et al. 
2014). The full length structure of the mouse SHANK3 gene comprises 5 
domains for protein-protein interactions: the ankyrin repeat domain (ANK), the 
SRC homology 3 (SH3) domain, the PDZ domain, the proline-rich region (PRO) 
and sterile alpha motif (SAM) domain (Figure 1.3). The N-terminal ankyrin 
repeat domain contains six ankyrin repeats, and interacts with the F-actin 
cytoskeleton via an interaction with α­fodrin (Duffney et al. 2015). The PDZ 
domain of SHANK3 interacts with MAGUKs via binding to GKAP (Naisbitt et al. 
1999). The PRO binds to Cortactin and Homer proteins, which are involved in 
the regulation of the cytoskeleton, synaptic plasticity and transmission 
(Monteiro & Feng 2017). Lastly, the C-terminal SAM domain is required for the 









Figure 1.2 | Structure and intragenic promoters of SHANK3.  
Schematic shows the structure of the mouse SHANK3 gene and the location of 
intragenic promoters indicated by the blue arrows. ANK: ankyrin repeat domain; 




Figure 1.3 | SHANK3 interacting proteins in the PSD.  
Representation of SHANK3 in the PSD is shown with its domains for protein-protein 
interaction. The ankyrin repeat domain (ANK) interacts with the F-actin 
cytoskeleton through an interaction with α-fodrin. The PDZ domain binds to GKAP, 
which then interacts with MAGUKs and the fragile X mental retardation protein 
(FMRP). The PRO domain interacts with F-actin through binding to Cortactin. The 




The SHANK3 gene was first implicated in neurodevelopmental disorders by 
studies of the 22q13.3 deletion syndrome, also known as Phelan-McDermid 
syndrome. This syndrome is characterised by autistic-like behaviours, 
intellectual disability, global developmental delay, and hypotonia (Prasad et al. 
2001). Over 600 cases of the 22q13.3 deletion syndrome have been reported, 
and the SHANK3 gene is deleted in nearly all cases (Phelan & McDermid 2012). 
SHANK3 haploinsufficiency is thus thought to be the cause of core 
neurodevelopmental and behavioural impairments observed in patients 
(Bonaglia et al. 2001). In rare cases where the 22q13.3 deletion leaves the 
SHANK3 gene intact, the individuals are phenotypically normal, further 
supporting the hypothesis that SHANK3 haploinsufficiency is responsible for 
neurological defects in the 22q13.3 deletion syndrome (Phelan & McDermid 
2012). 
 
Apart from the 22q13.3 deletion syndrome, many SHANK3 mutations have been 
found in nonsyndromic ASD (Durand et al. 2007; Gauthier et al. 2009; Boccuto 
et al. 2013; Moessner et al. 2007) and schizophrenia (Gauthier et al. 2009; 
Durand et al. 2007; Moessner et al. 2007; Boccuto et al. 2013) (Table 1.1). 
These mutations include nonsense mutations, missense mutations and small 
deletions, most of which are de novo variants. Recently, mutations in SHANK1 
and SHANK2 have also been found in ASD (Leblond et al. 2012; Boccuto et al. 
2013; Sala et al. 2015). A meta-analysis of SHANK mutations show that 
individuals with SHANK3 mutations have more severe cognitive impairment 
than those with SHANK1 or SHANK2 mutations  (Leblond et al. 2014). The 
difference in the degree of cognitive impairment might be explained by the 
expression pattern of the mutated SHANK3 protein in the brain, and by the 
extent to which the remaining two SHANK proteins can compensate for the loss 
(Monteiro & Feng 2017). Although all members of the SHANK protein family are 
widely expressed in the mouse brain including areas like cortex, thalamus and 
hippocampus, only SHANK3 mRNA is highly expressed at cortico-striatal 
glutamatergic synapses (Peça et al. 2011).  Cortico-striatal dysfunction has been 
implicated in repetitive behaviour in mice (Welch et al. 2007) further 
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implicating the potential importance of SHANK3 in ASD. It is worth noting that 
not only SHANK3, but its numerous interacting proteins are also associated with 
ASD and/or intellectual disability, including GKAP (Li et al. 2014), the fragile X 
mental retardation protein FMRP (Steinberg & Webber 2013), Homer1 
(Kelleher III et al. 2012), MAGUK protein PSD95 (Feyder et al. 2010), SYNGAP1 
(Hamdan et al. 2009; Hamdan et al. 2011; Mignot et al. 2016; Kimura et al. 
2018) and NMDAR subunits GluN1 and GluN2B (O’Roak et al. 2012) (see Figure 
1.3).  
 
Animal models of SHANK3 deficiency display ASD-like behaviours such as social 
avoidance, self-injurious grooming, and deficits in learning and memory (see 
Table 1.2), along with NMDAR hypofunction (Duffney et al. 2015), and altered 
levels of synaptic proteins including GluN2B, Homer proteins, SYNGAP1, 
metabotropic glutamate receptor 5 (mGluR5) (Peça et al. 2011; Zhou et al. 
2016). Together these findings strongly indicate there is a common molecular 
pathology involving NMDAR complexes. Given a wide range of synaptic proteins 
that SHANK3 interacts with, it is important to investigate how mutations in 
SHANK3 might affect the structural and functional organisation of NMDAR 
complexes at the PSD. This information will provide an insight into how 
























ASD (1 case) 
 
 
Severe ID and absence of language. 
Impaired social interaction. 
Low noise threshold.  




ASD (1 case) 
 
Language defects at 18 months of age. (Gauthier et al. 
2009) 
 
Exon 4 (ANK) 
 
 
ASD (1 case) 
 
High sensitivity to touch. 
Developmental delay & seizures.  
Repetitive speech (echolalia). 
(Boccuto et al. 
2013) 
 
Exon 8 (ANK) 
 
 
ASD (2 cases) 
 
Restricted interests and repetitive behaviours. 
Communication and social interaction deficits. 
Brisk reflexes and generalised hypotonia.  
(Moessner et 
al. 2007; 
Durand et al. 
2007) 
Exon 11 (SH3) ASD (1 case) 
 
Individual also has mutation in Neurexin 1.  (Boccuto et al. 
2013) 
Exon 16 (PDZ)  
 
ASD (1 case) 
 
Splice site mutation (intron 15-exon 16). 
Asperger syndrome. 
Behavioural deficits and echolalia at 2 years.  
(Boccuto et al. 
2013) 
Exon 19  
 
ASD (1 case) 
 
Splice site mutation (exon 19-intron 19). (Durand et al. 
2007) 





ASD (8 cases) 




Severe ID (8 cases).  
Mild-moderate ID (3 cases). 
Absence of verbal communication (4 cases). 
Severely impaired speech (2 cases). 
Global developmental delay (6 cases). 
(Leblond et al. 
2014; Boccuto 
et al. 2013; 
Durand et al. 
2007; Gauthier 
et al. 2010)  
 
Table 1.1 | Human SHANK3 mutations.  















































 sniffing  self-
grooming 
N/A Normal Impaired (Bozdagi et 
al. 2010; 
Yang et al. 
2012) 
 density Abnormal  self-
grooming 
 Impaired Impaired (Wang et al. 
2011) 








N/A Normal  rearing in 
new 
environment 




Normal Abnormal Self-injurious 
grooming 
N/A Impaired Mildly 
impaired 
(Schmeisser 
et al. 2012; 
Vicidomini 







 density Abnormal Self-injurious 
grooming 
 Normal N/A (Peça et al. 
2011) 
 density Abnormal Self-injurious 
grooming 










 Impaired Impaired (Kouser et 
al. 2013) 
N/A N/A Normal  Mildly 
Impaired 
Impaired (Speed et al. 
2015) 
 number Abnormal Self-injurious 
grooming 









 Impaired Impaired (Wang et al. 
2016)  
Table 1.2 | Characterisation of the SHANK3 mutant mice.  
Morris water maze is a test of spatial learning and memory. Rotarod testing measures 










1.3 SYNGAP1  
SYNGAP1 is another NMDAR-interacting protein, and associates with SHANK3 
(Sakai et al. 2011) through NMDAR complexes (see Figure 1.1). SYNGAP1 
directly interacts with MAGUKs such as PSD95 (postsynaptic density protein 
95) and SAP102 (synapse-associated protein 102) (Kim et al. 1998), and 
preferentially binds to GluN2B containing NMDARs  (Kim et al. 2005).   
 
SYNGAP1 is a brain-specific Ras GTPase activating protein (GAP), which 
negatively regulates Rap and Ras GTPases and their downstream signalling 
(Pena et al. 2008; Krapivinsky et al. 2004). SYNGAP1 is one of the most 
abundant PSD proteins (Cheng et al. 2006) and is activated by Ca2+/calmodulin-
dependent kinase II (CaMKII) (Krapivinsky et al. 2004). SYNGAP1 physically 
interacts with the small G proteins, which in turn play a role as molecular 
switches by cycling between an active guanosine triphosphate (GTP)-bound 
conformation and an inactive guanosine diphosphate (GDP)-bound 
conformation (Figure 1.4). GTPases have a slow intrinsic GTPase activity, and 
GAPs such as SYNGAP1 enhances the hydrolysis of GTP to GDP by 105-fold 
(Chen et al. 1998). Conversely, guanine nucleotide exchange factors (GEFs) 
facilitate the reverse process by exchanging GDP to GTP. The workings of GAPs 
and GEFs ensure appropriate levels of the small G protein activation in cells 
(Bos et al. 2007).  
 
The small GTPase Ras mediates the activity of a cytoskeleton protein, F-actin, 
which regulates dendritic spine formation and synaptic connection (Jeyabalan & 
Clement 2016). Ras also activates the extracellular signal-regulated kinases 
(ERK) pathway, which transmits signal downstream and leads to the 
transcription of genes involved in neurite and spine development (Vadodaria & 
Jessberger 2013). The Ras-ERK pathway is an essential modulator of synaptic 
strength and structure during NMDAR-dependent long-term potentiation (LTP) 
(Figure 1.5). By altering the number of AMPA receptors in the cell membrane, 
postsynaptic neurons directly regulate its sensitivity to glutamate and the 
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probability to generate an action potential (Krab et al. 2008). Together these 
findings illustrate a potential mechanism by which SYNGAP1 regulates neurite 
and spine maturation (Vadodaria & Jessberger 2013), and synaptic physiology 





Figure 1.4 | Small GTPase signalling. 
Upstream signalling such as NMDAR activation modulates the activity of GAPs (GTPase 
activating proteins; e.g. SYNGAP1) and GEFs (guanine nucleotide exchange factors) thereby 
mediating small GTPases such as Ras. GEFs promote activation (GTP-bound form), while 
GAPs facilitate inactivation (GDP-bound form). The active small GTPase binds to 




Figure 1.5 | Ras-ERK pathway in neurons. 
The Ras-ERK pathway is recruited for synaptic plasticity. Synaptic strength is strongly 
dependent on the number of AMPA receptors present in the PSD. Upon the activation of 
the NMDA receptors, the ERK pathway alters synaptic strength by mediating the insertion 
of AMPA receptors.  
 
 
Although SYNGAP1 homozygous knockout mutations in mice are lethal at early 
postnatal stages, heterozygous SYNGAP1 mice are viable with several 
behavioural and electrophysiological deficits (Table 1.3). NMDAR hypofunction 
may contribute to the altered behaviours, since lack of SYNGAP1 disrupts 
NMDAR-dependent synaptic transmission and learning (Komiyama et al. 2002; 
Clement et al. 2013). SYNGAP1 haploinsufficiency impairs the excitatory-
inhibitory balance in the developing cortex and hippocampus (Aceti et al. 2015), 
and leads to precocious synaptic maturation (Clement et al. 2012). SYNGAP1 
also plays a role in NMDAR-dependent regulations of synaptic density, spine 
morphology and synaptic plasticity (Kim et al. 2003; Vazquez et al. 2004; 
Rumbaugh et al. 2006).  
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Mutation (reference) Behavioural 
testing 
Electrophysiology Comments 
Het KO mice in a C57BL/6 
background (Komiyama et 
al. 2002)  
Slow learning.  LTP deficit Altered levels of active 
form ERK and Ras. 
Hom KO mice in a C57BL/6 
background (Vazquez et al. 
2004)  
N/A   mEPSC amplitude and 
frequency 
Precocious spine 
maturation and larger 
dendritic protrusions. 
Het KO mice in a C57BL/6 
background (Rumbaugh et 
al. 2006)  
N/A  synaptic transmission   ERK activation.  
Het KO mice in a 129 and 
C57BL/6 
mixed background (Carlisle 
et al. 2008)  
N/A LTD deficit  Levels of Ras and Rac. 
Het KO mice in a 129 and 
C57BL/6 
mixed background (Guo et 
al. 2009) 
Social recognition 
memory deficit, social 
isolation preference.  
 N/A Less responsive to 
NMDAR antagonist MK-
801.   
Same as Vazquez et al., 
2004 (Muhia et al. 2010) 
Severe working and 
reference memory 
deficits. 
N/A Neurogenesis deficit. 
Hippocampus-specific KO in 
mice in a 129 and C57BL/6 
mixed background (Muhia 






 sEPSC amplitude,  





Same as Guo et al., 2009 








of dendritic spine. 
Same as Guo et al., 2009 
(Clement et al. 2013)  
N/A LTP deficit, 
 ratio of 
AMPAR/NMDAR current 
Altered critical period 
of plasticity. 
Forebrain glutamatergic 
neurons-specific KO in a 
129 and C57BL/6 
mixed background (Ozkan 





  mEPSC amplitude and 
frequency  
Conditional KO.  
Table 1.3 | Characterisation of the SYNGAP mutant mice.  
Most studies used heterozygous null mutant mice maintained in a C57BL/6 background or a 
129 and C57BL/6 mixed background. The mouse line from Carlisle et al. (2008) was 
maintained in the mixed background as it breeds poorly in a single C57BL/6 background.  
 
The difference in phenotypic results might be explained by the methodological difference in 
phenotypic data analysis. Standardising the phenotyping analyses would be necessary for 
the future experiments.  
 
LTP: long-term potentiation; mEPSC: miniature excitatory postsynaptic current; sEPSC: 






The SYNGAP1 gene is located on mouse chromosome 17 (6p21.3 in humans) 
and gives rise to multiple protein isoforms with several functional domains 
(Figure 1.6). Each isoform contains the GAP domain that enhances the activity 
of small GTPases. Three different isoforms (SYNGAP1 A, B, and C), which differ 
in their N-termini arise from multiple promoter regions, and are regulated by 
synaptic activity and postnatal ages (McMahon et al. 2012). SYNGAP1 A and B 
carry a complete pleckstrin homology (PH) domain, which mediates protein-
protein interaction and lipid binding (Lemmon 2004). SYNGAP1 C has neither a 
unique amino acid sequence nor a complete PH domain. The C2 domain 
mediates binding to phospholipid and/or Ca2+ (Südhof & Rizo 1996), and a 
proline-rich region (PRO) binds to SH3 domains (Cohen et al. 1995). The C-
terminal coiled-coil domain (CC) facilitates the SYGNAP1 trimerisation (Zeng et 





Figure 1.6 |SYNGAP1 isoforms. 
Different isoforms of SYNGAP1 vary in both N-terminal and C-terminal (γ isoform 
not shown). PH: pleckstrin homology; GAP: GTPase activating protein; PRO: proline-




Alternative splicing of SYNGAP1 also leads distinct C-terminal isoforms (α1, α2, 
β and γ), which modulates interactions of SYNGAP1 with other PSD proteins 
(McMahon et al. 2012).   SYNGAP1 α1 is the most studied C-terminal isoform, as 
it carries the four amino acids (QTRV) necessary for binding PDZ domains 
(Figure 1.6). SYNGAP α2, β and γ lack this PDZ-binding domain. Although all 
these splice variants are wildly expressed throughout the brain, α2 and γ 
isoforms are less abundant (Li et al. 2001). Several studies have demonstrated 
the binding of SYNGAP1 α1 to PDZ domains of PSD95 plays an important role in 
regulating the composition of the PSD (Zeng et al. 2016; Walkup et al. 2016). 
Together the above findings indicate an additional role of SYNGAP1 in 
postsynaptic scaffold protein interactions.     
 
SYNGAP1 de novo mutations have been identified in autism spectrum disorders 
(Berryer et al. 2013), intellectual disability (Hamdan et al., 2009; Hamdan et al  
2011; Rauch et al., 2012; Mignot et al., 2016), and epilepsy (von Stülpnagel et al. 
2015) using exome sequencing or the candidate gene approach (Table 1.4). 
Deleterious mutations in SYNGAP1 are distributed throughout the gene, 
although the first two and last two exons (exon 1, 2 and 18, 19) are spared, as 
well as exons 9 and 16, which are present in all known isoforms (Mignot et al. 
2016).  
 
SYNGAP1 is one of the most common causes of intellectual disability and 
accounts for up to 1% of patients with intellectual disability (Mignot et al. 
2016). Recently, a large genetic study analysed the exomes of 4293 families 
containing individuals with developmental disorders and found that SYNGAP1 
is one of the six most significantly associated genes (Deciphering Developmental 
Disorders Study 2017). The question remains whether GAP deficiency is 
responsible for the pathological phenotypes observed in both human and 
animal models. Alternatively, or additionally, the lack of protein-protein 













Clinical features and comments 
1 Intron 1- exon 9 





Developmental delay.  
2 Exon 4 (PH) Nonsense Mild ID, ASD Neurological examination normal. 
3 Exon 5 (PH) Nonsense Moderate ID 
 
Global hypotonia, gait ataxia. 
4 Exon 5 (PH) Nonsense Severe ID, 
ASD 
Truncal hypotonia. 
5 Exon 5 (PH) Frameshift Severe ID, 
ASD 
Absence of speech, clumsy gait. 
6 Exon 5 (PH) Nonsense Severe ID, 
ASD 
Facial and truncal hypotonia, broad-
based gait. 
7 Intron 5 (PH) Splice site Moderate ID 
 
Truncal hypotonia. 
8 Exon 8 (C2) Frameshift Moderate ID Facial hypotonia with drooling, ataxic 
gait. 
9 Exon 8 (C2) Frameshift Moderate ID Truncal hypotonia, gait ataxia. 
10 Exon 8 (C2) Nonsense Severe ID, 
ASD 
Absence of speech, truncal 
hypotonia, gait ataxia. 
11 Exon 10 (GAP) Nonsense Severe ID Absence of speech, swallowing 
difficulty. 
12 Exon 11 (GAP) Missense Severe ID Absence of speech, mild gait ataxia. 
13 Exon 12 (GAP) Nonsense Severe ID Absence of speech, hyperactive deep 
tendon reflexes, unsteady gait.  
14 Exon 13 (GAP) Frameshift Mild ID, ASD Moderate akinesia, gait ataxia, 
truncal hypotonia. 
15 Exon 15 (PRO) Frameshift Moderate ID Truncal hypotonia, truncal tremor, 
ataxic gait. 
16 Exon 15 (PRO) Frameshift Severe ID, 
ASD 
Absence of speech, truncal 
hypotonia. 
17 Intron 15 (PRO) Splice site Severe ID, 
ASD 
Absence of speech, wide-based gait. 
Table 1.4 | Human SYNGAP1 mutations.  
Molecular and clinical features of human SYNGAP1 mutations. PH: pleckstrin 
homology; GAP: GTPase activating protein; PRO: proline-rich domain; ASD: autism 










We hypothesise GAP deficiency is the major contributor of the disease 
phenotypes, because molecular pathway network analyses for ASD-associated 
genes revealed the convergence upon the Ras-ERK pathway (Wen et al. 2016) in 
which SYNGAP1 is involved. Correspondingly, SYNGAP1 null mutants display 
abnormal levels of several components of the Ras-ERK pathway. If GAP 
deficiency is responsible, there is a potential to develop a new pharmacotherapy 
for patients with SYNGAP1 haploinsufficiency, as GAP function is more easily 
targetable than the structural function of SYNGAP1.  
 
Collectively, the aforementioned findings indicate the structural and functional 
interplay between SHANK3 and SYNGAP1 in NMDAR complexes. Both SHANK3 
and SYNGAP1 are enriched at the PSD, associate with each other, and are 
implicated in the same set of neurodevelopmental disorders. Despite the 
common features, however, SYNGAP1 and SHANK3 loss-of-function mutations 
significantly differ in their functional synaptic deficits: while reducing SYNGAP1 
leads to premature dendritic spine formation and increased synaptic 
transmission (Clement et al. 2012), lack of SHANK3 reduces the size and density 
of the PSD, and decreases synaptic transmission (Bozdagi et al. 2010; Peça et al. 
2011). In addition, while SHANK3 homozygous knockout animals are viable 
(Bozdagi et al. 2010), SYNGAP1 null mice die within a week (Komiyama et al. 
2002; Kim et al. 2003). It remains therefore to be investigated how mutations in 
distinct synaptic proteins result in the same set of neurodevelopmental 
disorders. We hypothesise that the NMDA receptor, SHANK3 and SYNGAP1 
form multi-protein complexes at the PSD, and that mutations in these genes 
disrupt the structural and/or functional architecture of NMDAR complexes 








1.4 CRISPR/Cas9 genome editing system 
To create novel mouse models with mutations in SHANK3 and SYNGAP1, we 
used a recently developed genome editing technology, the CRISPR/Cas9 system 
(Ran et al. 2013). Historically, targeted gene mutation has been achieved by 
homologous recombination (Capecchi 2005). However, the vector construction 
is time-consuming, and the low efficiency of homologous recombination in 
mammalian cells limits the utility of this approach. Although RNA interference 
(RNAi) can facilitate inexpensive and high-throughput investigation of gene 
function (Elbashir et al. 2001), it is limited by offering only temporary inhibition 
of gene function (Alic et al. 2012). Other recent methods using engineered 
nucleases such as Zinc-finger nucleases (ZFNs) and Transcription activator-like 
effector nucleases (TALENs) can produce a permanent mutation by introducing 
a targeted double stranded break (DSB) in the chromosome (Miller et al. 2011; 
Urnov et al. 2010). However, engineering these nucleases is laborious and 
costly, hindering their widespread use (Ran et al. 2013). The CRISPR/Cas9 
system is significantly easier to design and cost-effective.  
 
CRISPR is the microbial clustered regularly interspaced short palindromic 
repeats (CRISPR) adaptive immune system that cleaves exogenous genetic 
elements using RNA-guided nucleases (Garneau et al. 2010). Three types (I-III) 
of CRISPR systems have been identified in a wide range of bacterial and 
archaeal hosts. Each system contains a group of CRISPR-associated (Cas) genes, 
noncoding RNAs and an array of direct repeats (Figure 1.7). These repeats are 
interspaced by protospacers, short adaptable sequences derived from foreign 
DNA targets, and together they comprise the CRISPR RNA (crRNA) array 
(Makarova et al. 2011). The protospacers are immediately preceded by a 
protospacer adjacent motif (PAM), which vary depending on the particular 
CRISPR system (Ran et al. 2013).  
 
The Type II CRISPR interference has become the system adapted for genome 
editing in mammalian cells due to its relative simplicity (Sapranauskas et al. 
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2011), comprising of the Cas9 (CRISPR-associated protein 9) nuclease, the 
crRNA array encoding guide RNAs, and trans-activating crRNA (tracrRNA) 
mediating the processing of the crRNA array into separate units (Garneau et al. 
2010). Each crRNA unit comprises a partial direct repeat and a 20 nucleotide 
(nt) guide sequence, which directs Cas9 to the DNA target via Watson-Crick 
base paring. In the Type II CRISPR system derived from Streptococcus pyogenes 
(which is the system used in this study), a 5’-NGG PAM sequence must 
immediately follow the target DNA. The CRISPR system is reconstructed in 
mammalian cells by expression of human codon-optimised Cas9 and the 
required RNA elements (Mali et al. 2013). In addition, the crRNA and tracrRNA 
are fused together to make a chimaeric, single-guide RNA (sgRNA). Cas9 can 
therefore be directed toward any locus in the genome in immediate adjacency of 























Figure 1.7 | CRISPR/Cas9-mediated immunity in prokaryotes.  
During the acquisition stage, an invading foreign DNA (or RNA) is captured and 
cleaved by endogenous Cas9, and it is subsequently incorporated into the CRISPR 
loci. The CRISPR loci are then transcribed and processed into crRNAs. Upon re-
infection, Cas9 complexed with the crRNA and tracrRNA cleaves the foreign DNA. 





Similar to ZFNs and TALENs, Cas9 facilitates genome editing by generating a 
double-stranded DNA break in the target locus. The resulting cellular repair 
mechanisms can be exploited to induce various types of mutations including 
deletion and point mutation (Cong et al. 2013) (Figure 1.8). CRISPR/Cas9 offers 
several advantages over ZFNs and TALENs, including the ease of design, the 
ability for multiplex genome editing, and higher editing efficiency (Ran et al. 
2013). 
 
Double-stranded breaks generated by Cas9 can be processed by two 
endogenous cellular pathways. In the error-prone end joining pathway, the 
break ends are re-joined by DNA repair machinery, which can result in random 
insertions or deletions (indels) at the site of the break (Dickinson & Goldstein 
2016). These indels stem not from canonical non-homologous end joining as 
had been previously assumed, but from another end joining pathway that 
involves DNA polymerase θ (van Schendel et al. 2015) (Figure 1.9A). An indel 
mutation present within the coding region of a gene can lead to a reading 
frameshift generating a premature termination codon (Vicente-Crespo & 
Palacios 2010). Transcripts containing premature termination codons are 
eliminated by nonsense-mediated mRNA decay mechanisms resulting in gene 
knock-out (Brogna & Wen 2009) (Figure 1.9A). On the other hand, when 
homologous DNA fragments (donor DNAs) are present, another process called 
the homology-directed repair (HDR) can take place (Figure 1.9B). A crucial step 
in HDR is DNA end resection which creates a long 3’ overhang that can invade 
the homologous DNA template (Liu & Huang 2016). Although HDR pathway 
occurs less frequently than end joining, it can be utilised to introduce precise 
modifications (Figure 1.9B) using a single-stranded DNA oligonucleotide as the 
donor DNA (Chen et al. 2011). The mutation in the donor DNA is copied into the 





Figure 1.8 | CRISPR/Cas9 genome editing. 
Double-stranded break repair facilitates gene editing. RNA-guided endonuclease, 
Cas9 generates targeted double-stranded break. The resulting repair pathways can 
be leveraged to induce deletion by the end joining mechanism as well as precise 











Figure 1.9 | DNA repair mechanisms.  
A. End joining: Cas9 guided by short RNA generates double-stranded break at the target 
region. This can be repaired by the error-prone end joining pathway with DNA polymerase 
θ. The end joining can produce small insertions or deletions at the site of the break. If indels 
are generated in protein-coding sequence, it can shift the reading frame resulting in a 
premature stop codon. The CRISRP/Cas9 technology uses this end joining repair pathway to 
produce loss-of-function alleles.  
 
B. Homology-directed repair: A donor DNA is introduced along with RNA-guided Cas9. 
DNA end resection generates a 3’ single-strand DNA tail which can invade homologous 
sequence in the donor DNA (For the detailed mechanism of end resection see Liu and 
Huang, 2016). The mutation (in red) present in the donor DNA is copied into the genome 








The flexibility and simplicity of the CRISPR/Cas9 system has enabled the 
development of numerous applications and improvements. In addition to 
extensive use for gene modification, the CRISPR/Cas9 system has been 
repurposed for transcription regulation using catalytically dead Cas9 (dCas9) 
(Dominguez et al. 2016). This application was first demonstrated by mutating 
two nuclease domains of Cas9 from Streptococcus pyogenes (Qi et al. 2013). The 
resulting nuclease-deficient dCas9 allows direct regulation of DNA transcription 
without altering DNA sequence. dCas9 can facilitate the recruitment of various 
effector proteins for transcription repression or activation (Gilbert et al. 2013), 
DNA methylation or demethylation (Liu et al. 2016) and histone modifications 
(Hilton et al. 2015). Within a few years of being customised for mammalian gene 
editing, the CRISPR system now offers a highly versatile toolbox for robust and 
precise modification of genome and epigenome. Moreover, the CRISPR system 
has been applied to a wide range of species from a flowering plant Arabidopsis 
thaliana (Bortesi & Fischer 2015) to a free-living nematode Caenorhabditis 
elegans (Dickinson & Goldstein 2016). 
 
The major criticism of any gene editing modalities is the possibility of 
unintended mutations at other sites in the genome (off-target) in addition to the 
targeted site (on-target) (Singh et al. 2014). As the CRISPR/Cas9 system targets 
genetic loci in a sequence-dependent manner, Cas9 may bind to off-target sites 
containing a similar sequence to the targeted sequence. However, a requisite 
PAM sequence limits binding to off-targets without the PAM sequence. The use 
of target selection software designed to minimise off-target activities is crucial 
(Ran et al. 2013; Naito et al. 2015). In addition, various methods for off-target 
detection are available including web-based prediction tools (Bae et al. 2014), 
deep sequencing (Cho et al. 2014), and chromatin immunoprecipitation (ChIP)-
sequencing (Wu et al. 2014). The web-based software has an intrinsic limitation 
as the software assumes that off-target sequences are similar to the on-target 
site, overlooking off-target sites with low sequence similarity (Zhang et al. 
2015). Deep sequencing measures off-target effects at rates ranging from 0.01 
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to 0.1% (Cho et al. 2014).  ChIP-seq has also been adapted to find off-target 
binding sites for a specific sgRNA complexed with dCas9 (Wu et al. 2014). 
Encouragingly, most published studies report very rare, if any, off-target 
mutations (Yang et al., 2013; Duan et al., 2014; Veres et al., 2014; Wu et al., 
2014). Overall, even with potential off-target effects, careful selection of the 
guide sequence will likely offer precise and effective gene modification.   
 
Genetically modified mice are crucial tools for understanding the functions of 
genes in health and disease. Conventionally, gene modification is first 
introduced in ES cells, derived from the inner cell mass of a blastocyst. The 
modified ES cells are then injected into wild type blastocysts to produce germ-
line chimaeras (Capecchi 2005). The CRISPR/Cas9 system offers one-step 
generation of genome engineered mice by directly injecting Cas9 mRNA and 
sgRNAs into zygotes (H. Wang et al. 2013; Yang et al. 2013; Mashiko et al. 2013). 
As zygote injection does not require complex and time-consuming ES cell line 
generation, it has been widely used in many laboratories to generate mutant 
mice (Oji et al. 2016). However, direct zygote injection has several limitations. 
The efficiency of complicated genome editing in mouse zygotes, including large 
deletions, gene knock-in and point mutations, varies among not only target 
genes but also among laboratories (Mashiko et al. 2013; Aida et al. 2015; 
Sakuma et al. 2015). It is therefore necessary to use cell lines to validate the 
efficiency of sgRNAs before the injection. Furthermore, the high incidence of 
mosaicism in founder mice complicates genotyping and phenotyping analyses 
(Yen et al. 2014; Oliver et al. 2015). Subsequent mating is necessary to produce 
fully homozygous mutant mice, making the amount of time similar to the 
conventional ES cell-mediated approach (Oji et al. 2016). The difference 
between zygote injection and ES cell-mediated approach is illustrated in Figure 








A. Zygote injection: mRNA of Cas9 and sgRNAs are directly injected to pronuclei of 
zygotes. The introduction of monoallelic or biallelic mutations at the one-cell stage 
results in mutant mice carrying a distinct mutation in all cell types. However, 
mutations occurred later than one-cell stage lead to mosaic founder mice.  
B. ES cell transfection: ES cells are transfected with Cas9 and sgRNAs. The cell line 
with the desired mutation can be expanded and injected into blastocysts to 
generate chimaeric mice.   
 
Both A & B: After the generation of founder mice, a series of mating follows to 




















 Zygote injection ES cell transfection 
Pros One step generation of mutant 
mice  (Fast and efficient) 
 
Precise and complicated genome editing 
Can perform control experiment, 
optimisation and cell differentiation 
analysis  
Cons Mosaicism in founder animals  Additional steps of ES cell line 
generation (slow and laborious) 
Table 1.5 | Zygote injection and ES cell-mediated methods. 
 
In the present study, we examined the feasibility of genome editing in mice 
using an ES cell-mediated approach. First, we engineered SHANK3 deletion in 
mouse ES cells using the CRISPR/Cas9 system. Although several studies 
reported the generation of SHANK3 knockout mice previously (See Table 1.1), 
these studies were solely based on gene targeting by homologous 
recombination. It remained therefore to be seen whether generation of 
CRISPR/Cas9-mediated knockout mice was possible, and the ES cells-based 
approach was necessary to evaluate the efficiency of the CRISRP/Cas9 system. 
After successfully generating a SHANK3 knockout mouse line, we introduced a 
novel point mutation in SYNGAP1 gene for the first time with an aim of 
generating a GAP-deficient mouse line. These new mouse lines will facilitate 
research into the structural and functional interplay of SHANK3 and SYNGAP1 
proteins in NMDAR complexes in vivo, and how the protein-protein interaction 








































































2.1 General procedures and materials 
The CRISPR/Cas9 genome editing in mouse ES cells was performed as 
previously described (Ran et al. 2013) with modifications detailed below. All 
oligonucleotides were purchased from Invitrogen with a synthesis scale of 25 
nmole, desalted and dry format.  
All chemicals were analytical grade and products of Sigma-Aldrich unless 
otherwise indicated. Molecular cloning was performed using chemically 
competent Escherichia coli DH10B (Durfee et al. 2008; Grant et al. 1990). All 
enzymes and buffer solutions were purchased from New England Biolabs. ES 
cell culture was performed using ES cell line E14TG2a (a gift from Bill Skarnes, 
Wellcome Trust Sanger Institute) derived from 129/Ola strain. All ES cell 
culture reagents were products of Thermo Scientific, except where specified. All 
animal procedures were performed in accordance with Institutional Animal 













2.2 Cloning using CRISPR/Cas9 backbone plasmid 
Design of sgRNAs: Mouse genomic DNA sequences were extracted from the 
Ensembl genome browser (http://www.ensembl.org/index.html) and analysed 
by Serial Cloner (Serial Basics). 20 nt guide sequences were identified by sgRNA 
Designer (http://www.broadinstitute.org/rnai/public/analysis-tools/sgrna-des 
ign) of which search algorithms were described previously (Doench et al., 
2014).  In order to clone the selected target sequences into a sgRNA-expressing 
plasmid pX330 (Addgene plasmid # 42230), each pair of oligos (Table 2.1) 
were synthesized in the form as follows: 
 
5’- CACCGNNNNNNNNNNNNNNNNNNN     – 3’ 
3’-     CNNNNNNNNNNNNNNNNNNNCAAA – 5’ 
 
CACC and AAAC (highlighted in grey) were appended as cloning overhangs.   In 
addition, a G-C base pair (underscored) substituted the 5’ end of the guide 
sequence due to the transcription initiation requirement for U6 promoter of 
pX330. This does not negatively affect targeting efficiency (Ran et al. 2013). 
Oligonucleotide annealing with phosphorylation: Oligonucleotides were 
resuspended and diluted in double-distilled water to make a final concentration 
of 100 µM. 1 µl of each pair of oligonucleotides was mixed with one unit of T4 
Polynucleotide Kinase and 1 µl of 10X T4 Ligase Buffer in a volume of 10 µl 
which was made up by double-distilled water. The oligonucleotide mixture was 
incubated at 37 °C for 30 minutes, heating to 95 °C for 5 minutes and then 
cooling gradually to room temperature. 1 µl of the annealed oligonucleotide was 




BbsI digestion: 100 ng of pX330 was added to a reaction containing 1 unit of a 
restriction enzyme BbsI, 1.5 µl of 10X Buffer 2.1 in a volume of 15 µl made up by 
double-distilled water. The digestion mixture was incubated at 37 °C for an hour 
and treated with 0.5 µl of Shrimp Alkaline Phosphatase for 1 hour.  
Digest/ligation mixture: The resulting digestion mixture (15 µl) was mixed 
with 2 µl of the diluted oligonucleotide mixture, 2 µl of T4 Ligase Buffer, and 1 µl 
of T4 Ligase. The digest/ligation mixture was incubated at room temperature 





2.3 Design of DNA repair templates   
The 100 nt single-stranded DNA donor oligonucleotides (ordered from 
Invitrogen) were designed with homologous flanking sequence centred around 
the predicted Cas9 cut site, and the desired point mutation along with Cas9-
blocking and restriction enzyme site mutations (see Chapter 4). Cas9-blocking 
and restriction enzyme site silent mutations (which do not change the amino 
acid sequence) were selected based on the frequency of occurrence of 

















































































































































Table 2.1 | Oligonucleotide sequences for CRISPR mice generation. 
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2.4 Chemical transformation  
Preparation of competent cells: Single DH10B colonies from lysogeny broth 
(LB) agar plate were inoculated into 10 ml LB media and incubated at 37 °C 
overnight with shaking. 100 µl of overnight culture was added into 10 ml of 
fresh LB media, and incubated at 37 °C for 3 hours with shaking. The cells were 
harvested by centrifugation at 2500g for 5 minutes at 4 °C. The supernatant was 
decanted, and the cell pellet was resuspended in 10 ml of ice cold CaCl2 and 
incubated on ice for 1 hour. The cells were collected by centrifugation at 2500g 
for 5 minutes at 4 °C. The cell pellet was resuspended in 1 ml of ice cold CaCl2. 
Transformation of competent cells: 7 µl of the ligation mixture containing the 
targeting vectors was added to 100 µl of competent DH10B cells, incubated on 
ice for 1 hour and then heat treated at 42 °C for 2 minutes in a water bath. The 
cells were then spread onto LB agar plates containing ampicillin (0.1mg/ml) 
and incubated at 37 °C overnight.  
 
2.5 Plasmid DNA preparation and sequencing   
Individual colonies were selected from LB agar plates containing ampicillin and 
inoculated 3 ml LB media with ampicillin and incubated at 37 °C overnight with 
shaking. Plasmid DNA was extracted using the Wizard® Plus Minipreps DNA 
Purification System (Promega) according to the manufacturer’s protocol. 
Plasmid sequencing was performed using U6 promoter primer (5’ 






2.6 Sequence analysis   
All sequencing was performed by Edinburgh Genomics, using Sanger 
sequencing. Reference mouse genomic DNA and peptide sequences were 
retrieved from Ensembl genome browser (http://www.ensembl.org/ 
index.html) aligned using MAFFT (http://www.ebi.ac.uk/Tools/msa/mafft/) in 
ClustalW output format. Chromatogram data were analysed using FinchTV 
(Geospiza, Inc). 
 
2.7 Embryonic stem cell culture  
Feeder-free ES cells were maintained in cell culture flasks coated with 0.1% 
gelatin (Sigma-Aldrich) in ES cell media containing G-MEM, 10% Foetal bovine 
serum (Hyclone), 1% sodium pyruvate, 1% nonessential amino acid, 2 mM L-
glutamine, 100 M 2-mercaptoethanol and 1000 U/ml leukemia inhibitory 
factor (Chemicon) at 37 C supplemented with 5% CO2. Cryovials containing 
frozen ES cells were quickly defrosted at 37 C and diluted and washed with the 
ES cell media before plating and grown at 37 C with 5% CO2.  Culture media 
were changed with every 24 hours and 2-3 hours before passage. ES cells were 
passaged by trypsinizing (incubating with 0.25% Trypsin-EDTA for 1-3 minutes 
at 37 C) and then by mechanically breaking up ES cell aggregates.  
Transfection of ES cells: pX330 with the target sequence insert was co-
transfected into ES cells (passage number 26) with the pPGKpuro (Addgene 
plasmid # 11349) encoding puromycin-resistance gene using Promega FuGENE 
HD transfection Kit. 3.3µg of DNA in total was transfected in 1:1 ratio of pX330 
and pPGKpuro into ES cells seeded 3 x 105 in a 6-well plate (9 cm2). For 
SYNGAP1 experiment, donor DNA oligonucleotides were co-transfected along 
with pX330 and pPGKpuro in 1:1:1 ratio.  
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One day after transfection, ES cells were split into a 100 mm petri dish (55 cm2). 
24 hours after plating, puromycin (Cayman Chemical) was applied for positive 
selection at a concentration of 2 μg/ml and taken off after 3 days. After 
recovering for seven days, the surviving cells were either harvested from the 
petri dish for functional testing of targeting vectors, or isolated by manual cell 
picking and plating into each well of a 48-well plate for clonal isolation of ES 
cells. Individual colonies were then expanded and duplicated into two 48-well 
plates for either genomic DNA extraction or freezing. To freeze, ES cell media 
was replaced with freezing media containing 10% DMSO and 10% Foetal bovine 
serum.  
 
2.8 DNA extraction from mammalian tissues     
For DNA extraction from the heterogeneous population of CRISPR/Cas9-
modified ES cells, the cells were scraped off from the petri dish using a cell 
scraper in warmed phosphate-buffered saline (PBS), and centrifuged at 1200 
rpm for 4 minutes. The cell pellet was resuspended in 500 μl of Tail Digestion 
Buffer (TDB; 50 mM KCl, 10 mM Tris-HCl, 0.1% Triton X100 and 0.4 mg/ml 
Proteinase K) and incubated at 56 °C overnight, followed by heat treatment at 
95 °C for 10 minutes.  
For DNA extraction from individual ES cell colonies, genomic DNA was extracted 
by using Wizard SV 96 Genomic DNA Purification System (Promega) according 
to the manufacturer’s protocol in a manual format. Briefly, DNA was purified 
from ES cell lysates by 96-well vacuum filtration using a vacuum pump and the 
Vacuum Manifold.  
DNA genotyping was completed using mouse ear-clips or tail samples. Biopsies 
were added to 100 - 300 μl of TDB and incubated at 56 °C overnight, followed by 
heat treatment at 95 °C for 10 minutes. 1-2µl of a DNA extract was used for 
Polymerase chain reaction (PCR) amplification.  
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2.9 PCR amplification 
Oligonucleotides used as PCR primers were designed using NCBI Primer-BLAST 
(https://www.ncbi.nlm.nih.gov/tools/primer-blast/). The PCR primers were 
designed to amplify 150-300 bp on either side of the target region for a total 
amplicon to be 300-600 bp to facilitate clear visualisation in agarose gel. PCR 
reactions were carried out in DNA Engine Tetrad 2 (MJ Research) or T100TM 
Thermal Cycler (Bio-Rad). Oligonucleotide sequences are listed in Table 2.1. 
Approximately 1 µg of genomic DNA template was added in a reaction 
containing 2X HotStarTaq Master Mix (Qiagen), 20 µM of forward and reverse 
primers in a volume of 25 µl made up by double distilled water. The standard 






Table 2.2 |Standard PCR cycling protocol. 
 
2.10 Restriction enzyme digestion 
PCR products were digested with restriction endonucleases Sau3AI or DraI. 10 
µl of PCR products were mixed with NEB 10X digestion buffer and the 
appropriate volume of water before adding 0.5 µl of the restriction enzyme. The 
digestion mixture was incubated at the 37C for 2 hours. Restriction fragments 
were size-separated by agarose gel electrophoresis as described below.  
Step Temp.  Time Number of cycles 
Initial 
denaturation 





















2.11 Agarose gel electrophoresis 
For analysis of DNA fragments, agarose gel electrophoresis was performed 
using Owl Mini Gel Electrophoresis Systems (Thermo Scientific) according to 
the manufacturer’s manual unless otherwise specified below. To visualise DNA 
under ultraviolet light, GelRed Nucleic Acid Stain (Biotium) was added to 
agarose gel. 8-10 µl of samples mixed with 6X Gel Loading Dye (Thermo 
Scientific) were loaded on the gel along with 6 µl of GeneRuler DNA Ladders 
(Thermo Scientific) in 1X TBE buffer (from 10X stock solution containing 108 g 
Tris base, 55 g Boric acid and 9.5g EDTA disodium salt). The gel system was 
connected to PowerPac HC High-Current Power Supply (Bio-Rad) and run at 
100-120 V for 45-60 minutes. The gel was imaged using GelDoc-It Imager (UVP) 
or Odyssey Fc Imaging System (LI-COR). 
 
2.12 T7 endonuclease assay 
PCR was performed using DNA from control ES cells (wild-type) and CRISPR-
treated ES cells (mutant). PCR products were then purified using Qiagen PCR 
Purification Kit according to the manufacturer’s protocol. 100 ng of WT PCR 
product and 100 ng of mutant PCR product were added to NEB Buffer 2 in a 
volume of 10 µl made up by double distilled water. The mixture was heated 
using PCR block at 95 °C for 5 min and cooled down to room temperature to 
anneal the PCR product. The annealed product was then digested with 1 μl of 
NEB T7 endonuclease I at 37 °C for 20 min. 2 μl of 0.25 M 
ethylenediaminetetraacetic acid (EDTA) was added to stop the reaction, and the 
digest was run on a 2.5% agarose gel as described above. The cleavage intensity 
was measured as previously described by Ran et al., 2013 and the detail of the 




2.13 Off-target analysis 
CRISPR/Cas9 target online predictor CCTop (Stemmer et al. 2015) was used to 
find potential off-target sites that differed from SHANK3 on-target sequence (5’ 
CCCCCAGCTATGCAAAGCGA 3’) by up to 4 nt. The 8 potential off-target sites 
(Table 2.4) were amplified by PCR from genomic DNA of the three selected ES 
cell lines, then purified using Qiagen PCR Purification Kit according to the 
manufacturer’s protocol. The PCR products were subsequently subject to 
sequence analysis as described above.  
 
Name Strand Mismatch Position Sequence (5’ to 3’) 
On-target + 0 chr15: 89521118 
(SHANK3 exon10) 
CCCCCAGCTATGCAAAGCGA 
Off-target 1 + 3 chr6:147732596 
(Intergenic) 
CCaCCAGCTATGCAAAtCcA 
Off-target 2 + 3 chr13:25563699 
(Intergenic) 
CCCaCAGCTATGCAtAGCtA 
Off-target 3 - 4 chr14:66171714 
(Exonic) 
CCCaCAGCTATGCAtAGCtA 
Off-target 4 - 4 Chr1: 24012440 
(Exonic) 
CCtaCAGaTATGCAAAGCcA 
Off-target 5 - 4 Chr9: 73007795 
(Exonic) 
CGCCCAGtTcTGCAAAGCaA 
Off-target 6 - 4 Chr8: 34270077 
(Intergenic) 
CCCaCAGtTATaCAAAGCcA 
Off-target 7 + 4 Chr19: 24085323 
(Intergenic) 
gCCCCAcCcATGCtAAGCGA 
Off-target 8 - 4 Chr18: 35884000 
(Intergenic) 
ttCaCAGCTATGCAAAaCGA 
Table 2.3 | List of off-target sites. 
Potential off-target sites that differed from on-target SHANK3 sequence by up 







2.14 Mouse colony establishment 
Mouse chimaeras were produced by injecting mutant ES cell lines into C57BL/6J 
blastocysts. The ES cell lines were cultured for at least three passages after 
thawing for blastocyst injection. The injection was performed in Central 
Bioresearch Services, University of Edinburgh. Chimaeras were crossed with 
C57BL/6J wild-type mice and the first heterozygotes were produced in the F1 
generation. The heterozygotes were then backcrossed with C57BL/6J wild-type 
mice. Inter-crosses between F2 heterozygotes were used generate homozygote 
mutant mice in the F3 generation.  
 
2.15 Forebrain brain extraction 
Dissection: All mice were dispatched by cervical dislocation. The brain was 
removed from the skull immediately and placed on a plastic plate covered with 
filter paper on ice. The cerebellum, olfactory bulb and midbrain were removed 
and discarded. The remaining forebrain was snap-frozen using liquid nitrogen 
and stored at – 80 °C until use.  
Protein extraction: Frozen brains were homogenised individually using a 
Dounce homogeniser with 3.5 ml of homogenisation buffer containing 10% 
sodium deoxycholate (DOC), 1 M Tris pH 9, 0.5 M NaF, 20 mg/ml 
phenylmethylsulfonyl fluoride (PMSF) made in 100 % ethanol, one protease 
inhibitor cocktail (Roche) tablet per 50 ml and 1% phosphatase inhibitor 
cocktail (Milipore). Homogenates were centrifuged at 23000 rpm for 15 
minutes at 4 °C. The supernatant was then aliquoted and frozen on liquid 
nitrogen. All homogenates were stored at -80 C and thawed on ice before use. 
Protein extracts were quantified using a Pierce BCA Protein Assay Kit (Thermo 




2.16 Western blot 
Separating proteins by SDS-PAGE: SDS-PAGE (Polyacrylamide gel 
electrophoresis) was performed with NuPAGE Bis-Tris 4-12% gradient gels 
using XCell SecureLock Mini-Cell (Invitrogen) according to the manufacturer’s 
instruction unless otherwise indicated below. Six microliter of HiMark Pre-
stained Protein Standard (Life Technologies) was loaded as molecular weight 
marker, and 10 l of each 1 mg/ml protein sample (i.e. 10 g) was loaded into 
each lane of the gel. The XCell SecureLock Mini-Cell was then connected to 
PowerPac HC High-Current Power Supply (Bio-Rad) and run at 160 V for 80 
minutes.   
Semi-Dry transfer: The gel was equilibrated in a small container containing 1X 
NuPAGE transfer buffer for 20 minutes. A nitrocellulose membrane (Bio-Rad), 
and blot filter papers (Bio-Rad) were soaked in 1X NuPAGE transfer buffer. The 
transfer stack was assembled in a Trans-Blot SD Semi-Dry Transfer Cell (Bio-
Rad) according to the manufacturer’s protocol. The transfer cell was connected 
to PowerPac HC High-Current Power Supply (Bio-Rad) and run at 15 V for 30 
minutes.   
Antibody probing and detection: The membrane was removed from the 
Western transfer assembly and inserted into a Falcon 50ml tube. The 
membrane was blocked with 10 ml 5% milk in PBS with Tween (PBS-T, 0.1% 
Tween20) for 1 hour at room temperature on a roller mixer (Stuart Scientific). 
The primary antibody was diluted (Table 2.4) in PBS-T and incubated with the 
membrane at 4 °C overnight. The membrane was washed in PBS-T for 3 x 5 
minutes in PBS-T. The secondary horseradish peroxidase (HRP) antibody (GE 
Healthcare, sheep anti-mouse) was diluted to 1:50,000 in 10 ml 1% milk PBS-T 
and incubated with the membrane on the roller mixer at room temperature for 
1 hour. SuperSignal West Femto Maxium Sensitivity Substrate (Thermo 
Scientific) was used as enhanced chemiluminescent substrate for HRP. Equal 
volumes of luminol/enhancer solution and stable peroxide solution were mixed 
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and protected from light. The final PBS wash (10 minutes) was poured off, and a 
total volume of 4 ml (i.e. 2 ml luminol + 2 ml peroxide) was incubated with the 
membrane for 5 minutes at room temperature. The membrane was then 
removed from the Falcon tube and wrapped in a clear plastic pocket (Office 
Depot). The membrane was imaged using Odyssey Fc Imaging System (LI-COR). 
 





















































This chapter describes the design and generation of a SHANK3 knockout mouse 
model using ES cells modified by the CRISPR/Cas9 system. Overview of mutant 
mouse generation is illustrated in Figure 3.1, and Figure 3.2 summarises the 
CRISPR/Cas9 experiment in ES cells.   
 
 
Figure 3.1 | Workflow of mutant mouse generation.  
ES cells from agouti blastocysts are modified by the CRISPR/Cas9 system. ES cell 
lines with a desired mutation are injected into wild-type blastocysts to generate 




Figure 3.2 | CRISPR/Cas9-mediated gene editing in ES cells.  
Illustration of stages for sgRNA design and cloning, functional validation and cell line 
development. The target sequence is cloned into a sgRNA expression vector pX330. 
Sequence-verified pX330 vectors are transfected into ES cells and assayed for their 
ability to introduce targeted DNA cleavage. Lastly, transfected cells are isolated 
individually and expanded to derive isogenic cell lines with distinct mutations.  
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3.1 Consideration of target sites  
The efficiency of the CRISPR/Cas9 genome editing depends on the specificity of 
a 20 nt guide sequence within its sgRNA (Ran et al. 2013). The guide sequence 
must immediately precede a 5’-NGG PAM site, allowing the 20 nt guide to anneal 
with the opposite strand to mediate Cas9 cleavage between 3 bp and 4 bp 
upstream of the PAM sequence (Jinek et al. 2012) .  
The mouse SHANK3 gene (ENSMUSG00000022623) sequence was obtained 
from the Ensembl genome browser, which lists four protein-coding transcripts 
(Ensembl: Shank3-201, 202, 203, and 207; Figure 3.3). To disrupt the 
expression of the major isoforms of SHANK3, three out of four protein-coding 
transcripts were considered for target selection (Figure 3.3).  
Target sites were searched using the CRISPR Design Tool provided by the 
protocol mentioned previously (Ran et al. 2013). Potential guide sequences 
were identified in the first several common exons (exon 3 to exon 10) of the 
three transcripts. As the first top guide sequences in exon 5 and exon 10 showed 
the highest guide quality scores, these sequences were incorporated into the 
sgRNA-expressing vector pX330. However, ES cells transfected with the 
resulting plasmids failed to survive after drug selection. The examination of the 
experimental procedures revealed that the PAM site was unintentionally added 
to the guide sequence in the cloning procedure. The requisite 5’-NGG PAM 
sequence itself should not be included in sgRNAs. Target selection was repeated 








Figure 3.3 | Genomic structure and splice variants of SHANK3.  
Schematic shows the full Shank3 mouse gene structure and four protein-coding 
transcripts listed in Ensemble database. Target exon in this study is indicated by the 
red arrow. Transcript Shank3-207 results in a relatively small protein (135 amino 
acids, aa) compared to other three transcripts (709 - 1805 aa), and lacks all of five 
major protein domains. Therefore, this transcript was not considered for target 
selection. Note that additional transcripts generated by alternative splicing and 




3.2 Target selection  
An alternative target site finder, the sgRNA Designer, was used to search for 
new guide sequences. This was because, unlike the tool we previously used, the 
sgRNA Designer implements a published sgRNA scoring algorithm optimised for 
high on-site efficacy of sgRNAs (Doench et al. 2014).  
As our intention was to establish gene deletion induced by premature 
termination, importance was focused on exons of SHANK3 that were present in 
all of the major isoforms. For this reason, only exon 5 and 10 were considered, 
as they had been previously analysed.    
Five guide sequences per each exon were initially considered for cloning. The 
selection criteria were the sgRNA quality score, and for the sequence to be on 
the sense strand (Table 3.1). Only the sense strand sequences were chosen 
because of ease of targeting vector construction. The first two guides from exon 
5 and the last three guides from exon 10 were selected for targeting vector 
construction (Figure 3.4) to attempt the targeting efficiency of sgRNAs with a 
























CGTTGCGGAGAACCTTCAGG antisense 0.71  
TCCGCTGGCGGGTAGCACAG antisense 0.49  
CGTTGTCCAACTGTGCCGCA antisense 0.48  
TCCACTGTGCTACCCGCCAG sense 0.39 G1 
CTGGCGGGTAGCACAGTGGA antisense 0.38  
CTGAAGGTTCTCCGCAACGG sense 0.35 G2 
TACCCGCCAGCGGAACGCAG sense 0.34  
CTACCCGCCAGCGGAACGCA sense 0.26  
TGGACTTCCGGACCCGAGAT sense 0.22  
GCTACCCGCCAGCGGAACGC sense 0.22  
CAACGCCACTGACCTCCTGA sense 0.19  













CGAGTGGCCTGGCATCCCCA sense 0.75  
CTTGCTCCAGAGGCTTCAGG sense 0.65  
TCACTGGCTGAGCGCTGTAA antisense 0.62  
GGAGGAGAAAGACCGTGACA sense 0.61 G3 
CCCCCAGCTATGCAAAGCGA sense 0.58 G4 
GGAGCAAGAGTTGATGAGGG antisense 0.52  
TGAGCGCTGTAAGGGCCGTG antisense 0.52  
TCTGGAGCAAGAGTTGATGA antisense 0.44  
GCTGAGCGCTGTAAGGGCCG antisense 0.44  
AGAGTTGATGAGGGAGGCTT antisense 0.39  
GGCCACCCCTGCCTGCTGAG antisense 0.39  
ATCAGCCCGCAGCTTCTCCA sense 0.38 G5 
Table 3.1 | SHANK3 guide sequences generated by sgRNA Designer. 
Top 12 guide sequences per exon are shown above. Highlighted guide sequences 
indicate five highest scoring sense guides. The guide sequences highlighted in green 














 G1: TCCACTGTGCTACCCGC/cut/CAG   
 G2: CTGAAGGTTCTCCGCAA/cut/CGG  
 






 G3: GGAGGAGAAAGACCGTG/cut/ACA  
 G4: CCCCCAGCTATGCAAAG/cut/CGA  
 G5: ATCAGCCCGCAGCTTCT/cut/CCA 
Figure 3.4 | Loci of the selected guide sequences. 
Guide sequences are highlighted in each target exon. The site of double stranded 











3.3 CRISPR vector construction 
Each guide sequence was cloned into pX330 carrying Cas9 and an invariant 
sgRNA backbone immediately downstream of the oligo cloning site (Figure 
3.5A&B). Digestion of pX330 with BbsI enabled the replacement of restriction 
sites with insertion of annealed guide oligos. The resulting recombinant plasmid 
was extracted and purified, and the successful integration of the guide oligos 
was verified by Sanger sequencing (Table 3.2).  
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A. In silico design 
 
B. Reagent construction 
 
Figure 3.5 | Target selection and sgRNA expression vector construction  
A. In silico design. 20 nt guide target (highlighted in green) must be followed by 5’-
NGG at its 3’ end in the mouse SHANK3 gene. DNA sequence highlights G4 guide 
sequence as an example.  
 
B. Reagent construction. Cloning of the guide oligos into pX330 containing Cas9 and 
the sgRNA backbone. The G4 guide oligo pair (green) contains the linker sequence 
(cloning overhangs) for ligation into the guide oligo insertion site in pX330. A G-C 
base pair (yellow rectangle) is appended at the 5’ end of the guide sequence for U6 
transcription initiation. The vector pX330 also contains selection markers such as 
ampicillin (Amp) resistance gene to aid the selection of positive colonies. BbsI 





Table 3.2 | Sequence validation of guide oligo insertion into pX330. 
Sequence of the insertion site of the recombinant pX330. A partial sequence of U6 






3.4 Functional testing of sgRNAs 
The five selected sgRNAs were transfected into ES cells to determine targeting 
efficiency in the first instance. T7 endonuclease I assay was used to detect indel 
mutations mediated by CRISPR/Cas9. T7 endonuclease I recognises and cleaves 
heteroduplex DNA formed after denaturing and annealing WT and mutant 
alleles (Figure 3.6). By measuring the fraction of cleavage DNA, Cas-mediated 
targeting efficiency can be estimated (Ran et al. 2013). 
PCR primers were designed to amplify 150-300 bp on either side of the target 
for a total amplicon size of 300-600 bp to facilitate clear visualisation of 
cleavage bands in agarose gel. Target cleavage band sizes were determined 
(Table 3.3) based on the size of PCR product, and the fact that Cas9 cleaves 
between 3 bp and 4 bp upstream of the PAM of the corresponding guide 
sequence (Jinek et al. 2012). 
 
sgRNA Guide oligo insertion site sequence 
- GAAA CACC  GGGTCTTCGAGAAGACCT  GTTTTAGAGCTAGAAATAGCAAGTTAAA 
G1 GAAA CACC GCCACTGTGCTACCCGCCAG GTTTTAGAGCTAGAAATAGCAAGTTAAA 
G2 GAAA CACC GTGAAGGTTCTCCGCAACGG GTTTTAGAGCTAGAAATAGCAAGTTAAA  
G3 GAAA CACC GGAGGAGAAAGACCGTGACA GTTTTAGAGCTAGAAATAGCAAGTTAAA 
G4 GAAA CACC GCCCCAGCTATGCAAAGCGA GTTTTAGAGCTAGAAATAGCAAGTTAAA 




Figure 3.6 | Schematic of T7 endonuclease I assay. 
Genomic DNA from the heterogeneous population of Cas9-targeted ES cells is 
amplified by PCR. Amplicons are denatured, and re-hybridised slowly to produce 
heteroduplex DNA. T7 endonuclease I cleaves heteroduplex DNA, whereas 
homoduplex DNA remains intact. Cas9-mediated targeting efficiency (indel 
percentage) is calculated on the proportion of cleaved DNA as determined by the 











Figure 3.7 | Mutation detection on transfected ES cells.  
T7 endonuclease I assay to test the efficiency of exon 5-targeting G1 and G2 
sgRNAs, and exon 10-targeting G3, G4, and G5 sgRNAs. White rectangles indicate 
WT PCR products, and coloured arrowheads present expected fragment sizes for 
each locus.    
 
 
sgRNAs  Target Full PCR 
product (bp) 
Cleavage 
band 1 (bp) 
Cleavage 
band 2 (bp) 
G1 Exon 5 448  271 177 
G2 Exon 5 448 335 113 
G3 Exon 10 437 354 83 
G4 Exon 10 437  259 178 
G5 Exon 10 437  284 153 






Figure 3.7 shows wild-type control for exon 5 has only one band corresponding 
to the size of the PCR product (448 bp), while exon 10 wild-type control has a 
nonspecific cleavage band (~380bp) in addition to the full size product (437 
bp). This does not interfere with analysis as the size is different from the target 
cleavage bands. ES cells transfected with G1, G4 and G5 sgRNAs had the two 
clear target cleavage bands with the expected sizes. In contrast, G2 and G3 
sgRNAs showed only nonspecific cleavage bands. Therefore, G2 and G3 sgRNAs 
were excluded from further analysis.  
The intensity of the PCR product and cleaved bands was quantified by 
ImageStudio (Table 3.4). For each lane, the fraction of the cleaved amplicon (f) 
was calculated with the following formula: f  = (b + c) / (a + b + c), where a is the 
intensity of the undigested PCR amplicon, and b and c are the intensities of each 
cleavage band. Indel percentage was estimated using the following formula: 
. Table 3.4 lists the quantification of cleavage 
band intensity (a, b, and c), the fraction of cleaved amplicon (f) and indel 
percentage (%). The targeting efficiency ranged from 7.7 % to 22.4 % with the 
highest efficiency in G4 (22.4 %). It is worth noting that the targeting efficiency 
does not correlate with the sgRNA scores calculated by the sgRNA Designer: G3 
sgRNA failed to target despite of having the highest sgRNA score of 0.61; G1 and 
G5 sgRNA have similar sgRNA scores of 0.39 and 0.38, respectively, but G5 sRNA 
was more than twice efficient as G1 sgRNA. Lastly, the efficiency estimation may 
be undervalued as DNA was extracted without clonal isolation. Taken together, 
three functional sgRNAs, G1, G4 and G5 were identified by T7 endonuclease I 
assay.  
 
sgRNAs  a  b  c f Indel (%) 
G1 33.6 3.2 2.65 0.148 7.7 
G4 14 5.81 3.44 0.398 22.4 
G5 23.4 5.78 5.17 0.319 17.5 
Table 3.4 | Estimation of indel percentage. 
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3.5 ES cell line generation   
Having confirmed the efficiency of the sgRNAs, a second transfection was 
performed with the 3 functional sgRNAs: G1, G4 and G5. After transfection, each 
colony was picked to produce an individual cell line with a specific modification. 
A total of 204 colonies were isolated (G1 = 59, G4 = 73, and G5 = 72 cell lines). 
Among those isolated, 72 (G1 = 16, G4 = 30 and G5 = 26 cell lines) were 
screened through T7 endonuclease I assay. 42 cell lines (62.5 %) had the target 
cleavage bands. These targeted cell lines were further examined by Sanger 

















3.6 Sequence analyses 
DNA sequence from the mutant clones (n = 42) were analysed by sequence 
alignment (Figure 3.8), examination of chromatogram (Figure 3.9) and 
translation to peptide sequences (Table 3.5). An example series of sequence 
analyses of two G4 sgRNA-treated cell lines is discussed below.  
Figure 3.8 illustrates sequence alignment of two ES cell lines G4-C07 and G4-
C17 with wild-type DNA. G4-C07 shows a perfect match with wild-type DNA 
upstream of double stranded break (DSB). After DSB, however, the sequence is 
poorly aligned. This suggests G4-C07 carries a heterozygous mutation. On the 
other hand, G4-C17 shows a precise alignment both upstream and downstream 
of DSB, indicating G4-C17 has a homozygous mutation of 1 bp insertion 
followed by 11 bp deletion.  
Figure 3.9 compares DNA chromatograms of the two cell lines. Consistent with 
sequence alignment, G4-C07 has single peaks before DSB, then double peaks 
after DSB indicating either only one allele has a mutation, or each allele has a 
different indel mutation (i.e. compound heterozygous). G4-C17, on the other 
hand, has single peaks throughout suggesting both alleles have the same 
mutation.  
Next, the homozygous DNA sequence was translated into the corresponding 
peptide sequence to predict if the indel mutation would change the reading 
frame resulting in premature termination. Table 3.5 highlights that the indel 





































Step 2: Sequence Alignment 
 
Wild-type  ACTCCAGTACCATTCAGGGAAACCCCCAGCTATGCAAAGCGACGGCGTCTGGCTGGCCCG 
   G4-C07  actccagtaccattcagggaaacccccagctatgcaaa-----gacagctggtgggtcgg 
      **************************************     *.*. ****. **.* *   




Wild-type  ACTCCAGTACCATTCAGGGAAACCCCCAGCTATGCAAAGCGACGGCGTCTGGCTGGCCCG 
   G4-C17  actccagtaccattcagggaaacccccagctg-----------ggcgtctggctggcccg 
           *******************************.           ***************** 
⟶ Conclusion: Homozygous 
Figure 3.8 | SHANK3 sequence alignment.  
DNA sequence of the target region of mutant ES cells are aligned with wild-type 
control sequence to study the nature of the mutation. Highlighted regions indicate 
the guide sequence of G4 sgRNA (i.e. target locus) of wild-type DNA. Asterisks (*) 




Figure 3.9 | Interpretation of chromatogram for sequence analysis.  
The highlighted region indicates the G4 guide sequence. G4-C07 contains double 
peaks after the DSB indicating heterozygosity, whereas G4-C17 carries single peaks 








Table 3.5 | DNA translation of G4-C17 cell line. 
Highlighted region indicates the reading frame shift and the asterisk (*) indicates 







Table 3.6 summarises the results from all ES cell lines analysed. 62.5% of 
transfected ES cells carried targeted mutations and 26.4% were homozygous 
mutations (Figure 3.10). The type of homozygous mutations varied including 
insertion (1- 3 bp), deletion (1-36 bp), and deletion (11-12 bp) with extra 
insertion (1 bp) (Table 3.7 and Table 3.8).  All 19 homozygous mutations lead 





Table 3.6 | Result of CRISPR-SHANK3 transfection. 
 
 
Figure 3.10 | CRISPR/Cas9-mediated SHANK3 targeting in ES cells. 
Introduction of heterozygous (Het) and homozygous (Hom) mutations into ES cells 
with three sgRNAs (G1, G4 and G5). The number of cells is labelled for each 
genotype. Overall data from all three sgRNAs are represented in percentage on the 
right most bar (Total). WT: wild-type control. 




G1 (Exon 5) 13/16 (81.3%) 7/13 (53.8%) 
G4 (Exon 10) 20/30 (66.7%) 8/20 (40 %) 
G5  (Exon 10 ) 12/26 (46.2%) 4/12 (33.3%) 
Total 45/72 (62.5%) 19/45 (42.2%) 
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Table 3.7 | SHANK3 exon 5 peptide sequences of homozygous G1 cell lines. 
Highlighted peptide sequences indicate missense mutations. All G1 cell lines contain 




Table 3.8 | SHANK3 exon 10 sequences of homozygous G4 and G5 cell lines. 
All homozygous mutant cell lines contain missense mutations (highlighted in grey) followed 
by premature termination codons (asterisks). Note G5-G5-C30, G5-C33, G5-C34 contain 
identical peptide sequences implying they were derived from a single colony. Three ES cell 
lines highlighted in italic (G4-C17, G4-C24 and G4-C23) were chosen for blastocyst injection.  
Mutation  Cell line SHANK3 exon 5 peptide sequences 







3bp ins G1-C10 ECPLSLAAQLDNATDLLKVLRNGGAHLDFRTRDGLTAVHCAHTYCGTQGH* 
4bp del G1-C15 ECPLSLAAQLDNATDLLKVLRNGGAHLDFRTRDGLTAVHCATRGTQGH* 
10bp del G1-C09 ECPLSLAAQLDNATDLLKVLRNGGAHLDFRTRDGLTAVHCATTQGH* 
11bp del G1-C14 ECPLSLAAQLDNATDLLKVLRNGGAHLDFRTRDGLTAVHCATRRGIDG* 


































11bp del  





12 bp del  


























Antisense mediated exon skipping is a form of alternative RNA splicing causing 
the mutated exon to be skipped over, which can restore the disrupted reading 
frame (Harding et al. 2007).  Cells will express the truncated, but still functional 
SHANK3 protein, had exon skipping restored the reading frame. It is therefore 
necessary to investigate the possibility of exon skipping-mediated reading 
frame restoration in the targeted ES cells. DNA sequence of flanking exons 
without each target exon (exon 5 or 10) was identified and translated into 
peptide sequence (Table 3.9). In case exon 5 is skipped over, exon 4 and 6 will 
be spliced together, and this will still change the reading frame leading to 
premature termination. Similarly, exon 10 skipping will result in premature 
termination. The results demonstrate even if exon skipping occurs in the 
targeted ES cells, there will be premature termination leading to the intended 
knockout mutation.  
 






















































Table 3.9 | Exon skip analysis.  
DNA sequence and the corresponding peptide sequence are compared between 
wild-type target exon (exon 5 and exon 10) and its respected skip. Both exon 5 and 
exon 10-skip lead to premature terminations indicated by asterisks.  
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3.7 Design of PCR primers for genotyping  
As mutant alleles with large deletions allow rapid and effective PCR genotyping, 
the top three G4 cell lines (G4-C17, G4-C23 and G4-C24) were chosen for 
blastocyst injections. These cell lines will be referred as C17, C23, and C24 
respectively henceforward.  
Two pairs of primers for each mutation were designed for a simple PCR-based 
genotyping of mice, with one pair to amplify wild-type DNA but not mutant 
DNA, and vice versa for another pair.  
The 3’ end of the PCR primer is critical for amplification as it is highly sensitive 
to mismatches (Yu et al. 2014). Theoretically, the indel mutation will disrupt the 
PCR amplification if the 3’ end of primers were designed to exactly cover the 
indel region. Conversely, primers skipping the indel region at its 3’ end will only 
be able to amplify mutant alleles. In view of this hypothesis, we designed wild-
type primers to overlap the indel site at the 3’ end, and mutant primers to skip 
the indel site but to cover 3 nucleotides immediately after DSB at the 3’ end 
(Figure 3.11). Thus, WT primers can amplify only wild-type alleles, while 
mutant primers can only amplify mutant alleles. 
Table 3.10 summarises how each primer was designed. As the indel mutation 
in C23 is 36 bp deletion, which is larger than one primer can cover, three 
different wild-type primers were designed, covering the beginning (C23W1), 
the middle (C23W2) or the end (C23W3) of the deletion. For C24, an additional 
wild-type primer (C24W2) was designed to accommodate extra 1 nucleotide 
(thymine, T) at the 3’ end, which is absent in the mutant allele. The same 
reverse primer (Rev1) was used for all forward primers leading to PCR product 
size ~ 376 bp. DNA was extracted from the corresponding ES cell lines and wild-
type ES cell. The annealing temperature of PCR was set to 65 C in order to 






Figure 3.11 | PCR primer design.  
Example primer design for ES cell line C17. A wild-type (WT) primer amplifies only 
wild-type DNA as it contains a region which is deleted in mutant, whereas a mutant 
primer amplifies the mutant allele only, as it skips the deletion site followed by 
three additional nucleotides at the 3’ end.   
 
  
Primer Sequence Note 
C17W1 ACCCCCAGCTATGCAAAGCGAC Covers C17 mutation (with insertion). 
C17M1 CAGGGAAACCCCCAGCTGGGC Skips C17 mutation with 3 nt at the 3’ end. 
C23W1 GCTATGCAAAGCGACGGCGT Covers the beginning of C23 deletion. 
C23W2 CAAAGCGACGGCGTCTGGCT Covers the middle of C23 region. 
C23W3 GGCGTCTGGCTGGCCCGAGTG Covers the end of C23 region. 
C23M1 CCATTCAGGGAAACCCCCAGCC Skips C23 deletion, includes 3 nt at the 3’ end. 
C24W1 TATGCAAAGCGACGGCGTC Overlaps C24 deletion excluding insertion. 
C24W2 TATGCAAAGCGACGGCGTCT Covers the exact C24 mutation (with insertion). 
C24M1 GGAAACCCCCAGCTATGCAACGG Skips the 24 mutation with 3 nt at the 3’ end. 
Rev1 ACCCCTAGCCCCAGCCTATC Results in PCR amplicon size 376 bp. 








Figure 3.12 | PCR genotyping. 
PCR genotyping result using the designed primers. Two pairs of allele-specific 
primers were identified per each cell line and highlighted in yellow for wild-type-
specific and in blue for mutant-specific.   
 
Figure 3.12 shows the result of PCR genotyping using the designed primers (9 
pairs in total). Six primer pairs (2 pairs for each cell line, highlighted) had the 
intended selectivity. C17W1, C23W1 and C24W1 (highlighted in yellow) 
amplified wild-type DNA but not the respective mutant cell line. C17M1, C23M1 
and C24M1 (highlighted in blue) amplified each mutant DNA but not wild-type 
DNA. The additional wild-type primers did not show specificity: the C23W2 and 
C23W3 primers amplified both wild-type and mutant alleles, whereas the 
C24W2 primer failed to amplify any allele. This means wild-type primers 
designed with the same principle for the similar mutations had different results. 
For example, both C17 and C24 mutations consist of 11-12 bp deletion with 
extra 1 bp insertion. While the C17W1 primer covering the C17 mutation 
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exactly had the intended specificity, the C24W2 primer of the C24 mutation 
failed. If the extra insertion was removed from the C24W2 primer, however, 
there was the intended specificity (C24W1). It is therefore advisable to consider 
designing several different wild-type specific primers when the indel mutation 
overlaps a larger region and/or contains both insertion and deletion.  
Together, an efficient PCR genotyping protocol was developed using two allele-
specific primers per each mutation: one for wild-type and the other for mutant. 
This means genotype of mice will be determined twice independently, once by a 
WT primer and again by a mutant primer. Thus, genotyping results will be less 
















3.8 Off-target analysis  
A major concern of CRISPR/Cas9 is off-target effects. Thus, we characterised all 
genomic loci containing up to three bp mismatches compared to G4 guide 
sequence (Table 3.11). Only two off-target sites were identified by 
CRISPR/Cas9 off-target predictor (Stemmer et al. 2015). All potential off-target 
sites have 3 or more bp mismatches demonstrating the high specificity of G4 
sgRNA to the target sequence. Six additional off-target sites with 4 bp 
mismatches were also identified for reassurance (Table 3.11). 
The eight off-target sites were amplified by PCR from genomic DNA of the 
selected ES cell lines and subsequently analysed by Sanger sequencing. No off-
target mutation was identified in any locus (Figure 3.13). This result is 
consistent with the previous finding that three or more bp mismatches abolish 
the Cas9 activity (Yang et al. 2013). Recent publications demonstrated the rate 
of off-target mutations is sufficiently low and thus not a significant concern (Wu 













Site name Direction MM Position Sequence (5’ to 3’) 
On-target 
(sgRNA G4) 
Forward 0 chr15: 89521118 
(Shank3) 
CCCCCAGCTATGCAAAGCGA 
Off-target 1 Forward 3 chr6:147732596 
(Intergenic) 
CCaCCAGCTATGCAAAtCcA 
Off-target 2 Forward 3 chr13:25563699 
(Intergenic) 
CCCaCAGCTATGCAtAGCtA 
Off-target 3 Reverse 4 chr14:66171714 
(Exonic) 
CCCaCAGCTATGCAtAGCtA 
Off-target 4 Reverse 4 Chr1: 24012440 
(Exonic) 
CCtaCAGaTATGCAAAGCcA 
Off-target 5 Reverse 4 Chr9: 73007795 
(Exonic) 
CGCCCAGtTcTGCAAAGCaA 
Off-target 6 Reverse 4 Chr8: 34270077 
(Intergenic) 
CCCaCAGtTATaCAAAGCcA 
Off-target 7 Forward 4 Chr19: 24085323 
(Intergenic) 
gCCCCAcCcATGCtAAGCGA 
Off-target 8 Reverse 4 Chr18: 35884000 
(Intergenic) 
ttCaCAGCTATGCAAAaCGA 
Table 3.11 | Off-target analysis of three targeted ES cells (C17, C23 & C24). 














Figure 3.13 | Off-target analysis of three targeted ES cells. 
Multiple sequence alignment of potential off-targets as well as on-target are shown. Each 
target site is highlighted. All off-target sights display a perfect alignment with WT indicating 
there is no off-target mutation. Note on-target (G4 sgRNA) shows the deletions as 
previously confirmed. Multiple Sequence alignment was performed using EMBL-EBI MAFFT.  
ON-TARGET (SHANK3) 
    WT    ATTCAGGGAAACCCCCAGCTATGCAAAGCGACGGCGTCTGGCTGGCCCGAGTGGCCTGGC 
   G17    attcagggaaacccccagctgggcgt-----------ctggctggcccgagtggcctggc 
   G23    attcagggaaaccccca------------------------------------gcctggc 
   G24    attcagggaaacccccagctatgcaa------------cggctggcccgagtggcctggc 
          *****************                                    ******* 
OFF-TARGET 1 
 WT-OT1   ttgttcagttctcagtttcagagagggaatggatccaccagctatgcaaatccatggcgg 
G17-OT1   ttgttcagttctcagtttcagagagggaatggatccaccagctatgcaaatccatggcgg 
G23-OT1   ttgttcagttctcagtttcagagagggaatggatccaccagctatgcaaatccatggcgg 
G24-OT1   ttgttcagttctcagtttcagagagggaatggatccaccagctatgcaaatccatggcgg 
          ************************************************************ 
OFF-TARGET 2 
 WT-OT2   ggctactgagcattgcaaaggccctatcacacctgagtcccacagctatgcatagctatg 
G17-OT2   ggctactgagcattgcaaaggccctatcacacctgagtcccacagctatgcatagctatg 
G23-OT2   ggctactgagcattgcaaaggccctatcacacctgagtcccacagctatgcatagctatg 
G24-OT2   ggctactgagcattgcaaaggccctatcacacctgagtcccacagctatgcatagctatg 
          ************************************************************ 
OFF-TARGET 3 
 WT-OT3   aactccctgaaggtacccactctggtcctgtacaccctacagatatgcaaagccatggcc 
G17-OT3   aactccctgaaggtacccactctggtcctgtacaccctacagatatgcaaagccatggcc 
G23-OT3   aactccctgaaggtacccactctggtcctgtacaccctacagatatgcaaagccatggcc 
G24-OT3   aactccctgaaggtacccactctggtcctgtacaccctacagatatgcaaagccatggcc 
          ************************************************************ 
OFF-TARGET 4 
 WT-OT4   aaatgatccacaacttgcttcgcccagttctgcaaagcaaaggctgtaatttggttcggt 
G17-OT4   aaatgatccacaacttgcttcgcccagttctgcaaagcaaaggctgtaatttggttcggt 
G23-OT4   aaatgatccacaacttgcttcgcccagttctgcaaagcaaaggctgtaatttggttcggt 
G24-OT4   aaatgatccacaacttgcttcgcccagttctgcaaagcaaaggctgtaatttggttcggt 
          ************************************************************ 
OFF-TARGET 5 
 WT-OT5   ctacagacaggaaaccccacagttatacaaagccaaggctggctgtgttctagtagactg 
G17-OT5   ctacagacaggaaaccccacagttatacaaagccaaggctggctgtgttctagtagactg 
G23-OT5   ctacagacaggaaaccccacagttatacaaagccaaggctggctgtgttctagtagactg 
G24-OT5   ctacagacaggaaaccccacagttatacaaagccaaggctggctgtgttctagtagactg 
          ************************************************************ 
OFF-TARGET 6 
 WT-OT6   tcattcttaaagcactggagattgaactcctggccccacgcatgctaagcgaaggccctg 
G17-OT6   tcattcttaaagcactggagattgaactcctggccccacgcatgctaagcgaaggccctg 
G23-OT6   tcattcttaaagcactggagattgaactcctggccccacgcatgctaagcgaaggccctg 
G24-OT6   tcattcttaaagcactggagattgaactcctggccccacgcatgctaagcgaaggccctg 
          ************************************************************ 
OFF-TARGET 7 
 WT-OT7   cagccctcgggactgtgtctctccaaggtacatccttcacagctatgcaaaacgatgggc 
G17-OT7   cagccctcgggactgtgtctctccaaggtacatccttcacagctatgcaaaacgatgggc 
G23-OT7   cagccctcgggactgtgtctctccaaggtacatccttcacagctatgcaaaacgatgggc 
G24-OT7   cagccctcgggactgtgtctctccaaggtacatccttcacagctatgcaaaacgatgggc 
          ************************************************************ 
OFF-TARGET 8 
 WT-OT8   cccattgacattgcctccatctttgcaaagtgaaggtcagccagaaggggctgcccagtc 
G17-OT8   cccattgacattgcctccatctttgcaaagtgaaggtcagccagaaggggctgcccagtc 
G23-OT8   cccattgacattgcctccatctttgcaaagtgaaggtcagccagaaggggctgcccagtc 
G24-OT8   cccattgacattgcctccatctttgcaaagtgaaggtcagccagaaggggctgcccagtc 
          ************************************************************ 
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3.9 Blastocyst injection and mouse generation 
Microinjection and subsequent chimera generation were performed in Central 
Bioresearch Services, University of Edinburgh. The three ES cell lines were 
injected into C57BL/6J mouse blastocysts in separate batches, which were then 
transferred into a pseudopregnant recipient mouse (Table 3.12). The ES cells 
were derived from the 129/Ola mouse strain carrying genes coding for agouti 
coat colour, which is dominant over black coat colour of the recipient C57BL/6J. 
Therefore, the resulting chimaeras presents patches of agouti.  
Adult male chimaeras with >50% agouti coat colour were mated with C57BL/6J 
mouse. Coat colours of the progeny are either agouti if 129/Ola ES cells 
contribute to chimaeras’ germ cells, or black if the recipient C57BL/6J blastocyst 
contribute to the germ cells. To confirm germline transmission of ES cell-
derived mutations, genomic DNA was extracted from ear clip biopsies of agouti 
pups and the target region was amplified by PCR, then sequenced using Sanger 
method. Those F1 agouti pups carrying the intended SHANK3 deletion were 
identified as germline transmitted heterozygous.  
 










C23 (25/09/2015) 67 4 6 1 0 n/a 
C17 (02/10/2015) 19 1 1 0 n/a  
C24(09/10/2015) 60 4 6 2 14 0 
C17 (23/10/2015) 62 4 0 n/a  
C23(22/01/2015) 60 4 12 1 42 2 
C17 (29/01/2015) 8 1 4 1 22 5 
C17 (23/02/2015) 12 22 2 1 46 3 
C17 (24/02/2015) 63 3 6 0 n/a 
C23(01/03/2015) 43 2 0 n/a 





Table 3.12 summarises the results of blastocyst injections of the ES cell clones. 
The initial microinjection of the C24 cell line produced two chimaeras, while the 
C17 cell line generated only one infertile chimaera and no chimaera were 
produced from the C23 cell line. Thus, microinjections of the C17 and C23 ES 
cell lines were repeated while waiting for F1 offspring of C24 to be sequenced. 
Later we found that the C24 cell line did not reach germline transmission, since 
no heterozygous mouse was produced from chimaera breeding. As the C17 and 
C23 cell lines contributed to germline, we focused our attention to these two 
lines to establish the working mouse colonies. Those F2 or F3 heterozygotes 
were used as founder mice to establish the working mouse colony. 
To examine the potential synaptic changes induced by SHANK3 deletion, F1 
heterozygous mice were further crossed with a mouse line carrying a double 
fluorescent tags in endogenous PSD95 and SAP102 proteins. PSD95 and SAP102 
are the members of MAGUK and integral part of NMDAR complexes (see Figure 
1.1). From this cross we have obtained multiple triple heterozygous mice. 
Further experiments using triple homozygous mice will investigate the effect of 












3.10 Review of PCR genotyping 
When the designed genotyping primers were used for identifying F2 mice, PCR 
produced poor results including no amplification, smear bands or unspecific 
bands. To resolve this issue, the primer design was reviewed. 
The melting temperature (Tm) of a primer is a critical value in performing a 
successful PCR, and Tm difference (∆Tm) of a pair of primers is to be less than 5 
C (Chuang et al., 2013).  We found that the Tm of the designed forward primers 
ranged from 65 – 72 C, whereas the reverse primer’s Tm was 59 C, resulting in 
∆Tm of 6 – 13 C (Table 3.13). This finding led us to consider reducing the Tm 
by redesigning primers. As the forward primers carrying unique designs confer 
the specificity to each genotype, we designed a new reverse primer with the 
higher Tm of 70 C, which results in PCR product size ~ 567 bp. The annealing 
temperature (Ta) of PCR was set to 65 C for wild-type reaction, and 69 C for 
mutant reaction to accommodate the raised average Tm.  
With the new reverse primer, PCR genotyping was performed and clear bands 
were obtained (Figure 3.14). The PCR genotyping results were subsequently 
compared with Sanger sequencing for validation. The sequencing results of 
more than eight F2 matched with the genotypes determined by PCR. Therefore, 













Table 3.13 | Genotyping primers. 
Tm was calculated by Tm Calculator (http://www6.appliedbiosystems.com/ 






Figure 3.14 | PCR genotyping of F2 mice (C17). 
Example of genotyping PCR results using genomic DNAs from wild-type SHANK3 
(WT) and heterozygous (Het), using either wild-type (W) or mutant (M)-specific 





Primer Sequence 5’-3’ Tm (C) ∆Tm 1   ∆Tm 2  
C17W1 ACCCCCAGCTATGCAAAGCGAC 65 6 5 
C17M1 CAGGGAAACCCCCAGCTGGGC 72 13 1 
C23W1 GCTATGCAAAGCGACGGCGT 66 7 4 
C23M1 CCATTCAGGGAAACCCCCAGCC 70 11 0 
Rev1 AGGCCCTCCTACCTGATCTT 59 - - 
Rev2 TGTGGGGGACGACGGACAGCCA 70 - - 
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3.11 Western blot validation  
To confirm SHANK3 deficiency in the newly generated mouse lines, total protein 
was extracted from forebrains of adult wild-type and SHANK3 KO mice and 
analysed by Western blot with an antibody raised against endogenous SHANK3. 
As shown in  
Figure 3.18, probing with the SHANK3 antibody (Santa Cruz, sc-377088) in all 
genotypes showed specific bands at approximately 200 kDa, 185 kDa, and 165 
kDa, and the 200 kDa band corresponding to transcript SHANK3-203 (200 kDa; 
See Figure 3.15) was most robustly detected. The smaller two bands might be 
splice variants of SHANK3-203 or SHANK3-201 (190 kDa). Note another 
protein-coding isoform SHANK3-202 (78 kDa) was not visible.  
The expression of the largest 200 kDa SHANK3 isoform is reduced in the C17 
heterozygous mice (Figure 3.166A) and completely absent in the homozygous 
mice (Figure 3.176C). The C23 heterozygous mice, however, showed no 
reduction in SHANK3 protein expression (note C23 homozygous mice were not 
available). To eliminate genotyping errors, each mouse was re-sequenced and 
the original genotype was confirmed. Therefore, the C23 mouse line was 
terminated and only the C17 mouse line were used for breeding.   
The above findings indicate although both mouse lines carry the indel mutations 
leading to premature termination codons, only one deletion (C17, 11 bp 
deletion) led to reduction in SHANK3 protein expression. A potential 
explanation for the discrepancy is that in C23 (36 bp deletion), translation 
termination at the premature stop codon could have been suppressed resulting 
in the full-length SHANK3 protein. Although translation termination is usually 
accurate, an error can occur (Keeling et al. 2012). In fact, suppression of 
translation termination is more frequent at premature termination codons at a 
rate of 0.01 to 1% (Bonetti et al. 1995; Cassan & Rousset 2001) than at normal 
stop codons at 0.001-0.1% (Parker 1989) respectively. cDNA synthesis by 
reverse transcription will allow detailed examination into the SHANK3 
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translation product of C23 mutation. Taken together, these data demonstrate 




Figure 3.18 | Western blot of forebrain homogenates from the new SHANK3 
mouse lines. 
Forebrain homogenates from wild-type, heterozygous and homozygous SHNAK3 knockout 
mice were subjected to Western blot with the SHANK3 antibody and the beta-actin 
antibody as a loading control (45 kDa). (A) The full length SHANK3 (~200 kDa; SHANK3-203) 
expression is reduced in the C17 heterozygous mice. However, the C23 heterozygous mice 
show the similar level of SHANK3 expression to the wild-type mice. (B) The second blot was 
performed Cathy McLaughlin using the same brain samples. Similar to the first blot, only 
C17 shows the reduction in the full length SHANK3. (C) Blot of heterozygous and 
homozygous C17 mice. The SHANK3-203 isoform was absent in the homozygous C17 mice.  
WT: wild-type. Het: SHANK3 KO heterozygous mice. Hom: SHANK3 KO homozygous mice. 





Figure 3.16 |The observed isoforms of SHANK3.  
The schematic of the observed isoforms which are likely to be affected by the deletion. The 
corresponding transcripts are predicted based on size (see Figure 3.3). Exons deleted in 
each of the existing mutant lines are indicated by red arrows (see Table 1.2), and the blue 
arrow indicates the exons deleted in the current study.  
 
References: 
(1) Peça et al., 2011 
(2) Bozdagi et al., 2010; Yang et al., 2012; Wang et al., 2011; Jaramillo et al., 2016 
(3) Lee et al., 2015 
(4) Schmeisser et al., 2012; Vicidomini et al., 2016  
(5) Peça et al., 2011; Mei et al., 2016 
(6) Kouser et al., 2013; Speed et al., 2015; Zhou et al., 2016 

































This chapter describes the design and generation of a mouse model containing a 
mutation in the GAP domain of SYNGAP1 using ES cells modified by the 
CRISPR/Cas9 system. The mutation was intended to selectively disrupt the Ras-
GTPase activating function of SYNGAP1 and thereby provide insight into the 
potential role of GAP-mediated catalysis in the pathophysiology of SYNGAP1 
haploinsufficiency. We refer to this mutation as GAP-deficient SYNGAP1 
hereinafter. 
 
4.1 Mutation rationale and design  
The GAP function of Ras-GAPs, including SYGNAP1, requires a highly conserved 
arginine amino acid in the active site of the Ras-GTPase domain  (Ahmadian et 
al. 1997; Scheffzek et al. 1997) (Figure 4.1). This “arginine finger” binds to the 
γ–phosphate and the β-phosphate of GTP, thereby neutralising the negative 
charge of the γ–phosphate that is removed during hydrolysis into GDP 
(Rehmann & Bos 2004). The arginine finger also helps to stabilise glutamine at 
position 61 in the GTPase, which in turn places a water molecule for a 
nucleophilic attack on the γ–phosphate (Scheffzek et al. 1997). 
The replacement of the invariant arginine finger by alanine in vitro dramatically 
reduces GAP-enhanced GTPase activity of other Ras-GAPs including p120GAP 
(Scheffzek et al. 1997) and neurofibromin (NF1) (Ahmadian et al. 1997). We 
therefore reasoned that changing the catalytic arginine (R470) of SYNGAP1 to 
alanine (R470A) will impair the GAP activity, while keeping other functions 
such as a structural role intact. Two additional amino acids, lysine and proline 
were also considered to substitute the SYNGAP1 catalytic arginine, as R470K 
and R470P mutations have been previously shown to disrupt the GAP activity in 
vitro (Pena et al. 2008). Consistently, all three mutations (R470A, R470K and 
R470P) resulted in the almost complete deficiency of the GAP function in 




Figure 4.1 | Active site of Ras GTPase-GAP complex. 
The arginine finger (Arg) moves into the active site of Ras, stabilising the transition 
state (i.e. the GTP hydrolysis process) of the Ras-GTPase activity. The carbonyl (C=O) 
group of the arginine finger forms a hydrogen bond with NH2 group of the 
Glutamine-61 (Gln, in green) of Ras. The glutamine-61, in turn, positions a water 
molecule (H2O, in blue) facilitating the attack on the γ–phosphate of GTP. The 
arginine finger also binds to the γ–phosphate and the β-phosphate and neutralises 









To introduce these mutations, we used the CRISPR/Cas9 system, which allows 
the introduction of a point mutation by the homology-directed repair (HDR) 
pathway. This results in error-free edits using an exogenous DNA as a donor 
DNA (see Figure 1.9B). The HDR process occurs most efficiently when the 
donor DNA contains at least 40 bp homology arms flanking the desired 
mutation (Chen et al. 2011; Ran et al. 2013). 
The design and construction of sgRNA-expressing vectors and donor DNAs were 
performed by David Kerrigan, a former technician in our lab. Briefly,  the 
CRISPR Design Tool (Ran et al. 2013) was used to identify potential guide  
sequences for exon 9 of mouse SYNGAP1 (ENSMUSG00000067629, 
chromosome 17) where the codon for arginine-470 is located. The highest 
scoring guide (5’-GGTAGACCGATTCATGGAGC-3’) was 17 bp upstream of 
arginine-470 (Figure 4.2A). Note this guide sequence scored the second best 
(0.63/1.0) in the alternative target search programme, the sgRNA designer 
(Doench et al. 2014), which was used for the SHANK3 guide selection (see 
Chapter 3). The SYNGAP guide was cloned into the sgRNA-expressing vector 
pX330 and the functional validity of the sgRNA was confirmed by T7 
endonuclease I assay following the procedures described in the last chapter.   
The 100 nt single-stranded DNA oligonucleotides were designed to serve as the 
donor DNAs (Figure 4.2B). The donor DNAs contained ~40 bp homology arms 
flanking the desired mutation on each side. The original arginine codon CGA 
(R470 in A0A0A6YVS6_MOUSE in Uniprot; https://www.uniprot.org/uniprot/ 
A0A0A6YVS6) was substituted to GCC (alanine), AAA (lysine) or CCT (proline). 
Additionally, all of the donor DNAs contain two silent mutations, which do not 
result in a change in the amino acid sequence. First, a restriction site, Sau3AI 
(for alanine and proline) or DraI (for lysine) was introduced to enable easy 
genotyping using restriction enzyme digestion. Secondly, the NGG PAM site was 
substituted (CGG to CGC) to prevent the Cas9 cleavage after correct editing 




A. Target region 





 CGG:  PAM site to be abolished (Cas9-blocking)  
 CATATTC: Restriction site to be introduced 
 CGA: R470 codon to be changed 
 
B. Donor DNA sequences   












C. R470A donor DNA design   
WT DNA CGG GAA CAC CTC ATA TTC CGA 
Mutant DNA CGc GAA CAC CTg ATc TTC gcc 
Amino acid  R   E   H   L   I   F  R>A 
464 465 466 467 468 469 470 
 
 R470 codon to be changed: CGA to gcc (Arginine → Alanine) 
 Introduction of Sau3AI site: CTC to CTg (Leucine); ATA to ATc (Isoleucine) 
 Cas9-blocking: CGG to CGc (Arginine) 
Figure 4.2 | Design of the donor DNAs.   
A & B. Target region and donor DNA sequences. DNA sequence data of wild-type 
exon 9 and the three donor DNAs. The guide sequence, the PAM site, the R470 
codon, and the restriction site are indicated in a distinct colour.  
C. R470A donor design. Mutations introduced in the donor DNA. An example R470A 
(alanine) donor DNA contains one missense mutation for substituting arginine-470 
with alanine and two synonymous mutations for the introduction of a restriction 




4.2 ES cell line generation  
ES cells were transfected with the SYNGAP1-targeting sgRNA along with the 
donor oligos (each carrying the R470A, R470K or R470P mutation). A total of 
572 colonies were isolated (R470A = 204, R470K = 144, and R470P = 224 
colonies) and screened by restriction enzyme digestion. DNA was extracted 
from each colony and the presence of the mutations was determined by analysis 
of PCR amplicons. PCR primers (SG1-E9-F and SG-E9-R) were designed to 
amplify ~130 bp on either side of exon 9 for a total amplicon size of 414 bp. PCR 
products were digested with the corresponding restriction enzymes, and 
separated by agarose gel electrophoresis for fragment size analysis (Figure 
4.3). A total of 147 cell lines (25.7%) had the expected fragment sizes (Table 
4.1) indicating these cells contain SYNGAP1 mutations (Figure 4.4A). These 















Figure 4.3 | The R470A cell lines genotyping using restriction digestion. 
Gel electrophoresis of Sau3AI-digested DNA fragments of the R470A ES cells. The 
undigested (U) control bands were slightly bigger (414bp) than the digested (C) full-
length bands (391 bp) due to an endogenous Sau3AI site at position 23 of the PCR 
product. The homozygous R470A cell lines (n=2) show two cleavage bands of 277 bp 
and 113 bp while heterozygous cell lines (n=3) present three bands of, 391 bp, 277 
bp and 113 bp. Wild-type ES cells show only one band of 391 bp. Note 113 bp bands 
are only visible in the electronic copy of this thesis; the smallest 23 bp fragment was 
not visible either due to small size. WT: wild-type control DNA. Hom: homozygous 
R470A cell line. Het: heterozygous R470A cell line. U: uncut (undigested) control 





Enzyme DNA Cleavage bands (bp) 
Sau3AI WT 391, 23 
R470A  or R470K Het: 391, 277, 113, 23 
Hom: 277, 113, 23 
DraI WT 414 
R470P Het: 414, 272, 142 
Hom: 272, 142 






Figure 4.4 | CRISRP/Cas9-mediated SYNGAP1 mutations in ES cells. 
The number of cell lines is indicated per each donor (R470A, R470K and R470P), and 
the overall frequencies (total) were shown in percentage. Overall, 25.7% of 
transfected cells carried SYNGAP1 mutations. 16.3% of targeted cells contain the 





4.3 Sequence analyses 
DNA sequence analyses of the PCR amplicons from each mutant cell line were 
performed as described in the previous chapter. Briefly, the undigested PCR 
products (414 bp) were purified, and sequenced by the Sanger method. DNA 
sequences from the mutant cells were aligned with wild-type DNA to identify 
any nucleotide mismatches (Figure 4.5). Additionally, DNA chromatograms 
were examined to confirm genotype.  
The results of sequence analyses are summarised in Figure 4.4B. The majority 
(78.9%) of the mutant cells contain either mono-allelic (36.7%) or bi-allelic 
indel mutations (42.2%). Six HDR events (4.8%) contained additional indel 
mutations. This might be due to the high nuclease activity of Cas9, which may 
continuously re-edit targeted sites until sufficient modification by the end 
joining pathway prevents further cleavage (Cong et al. 2013; H. Wang et al. 
2013; Paquet et al. 2016).  
A total of 24 clones contained the precise HDR editing, making the overall HDR 
efficiency of 4.2% (24/572 cell lines). Notably, all accurate HDR mutations were 
homozygous. A potential explanation for the lack of heterozygous HDR 
mutations may be the high efficiency of Cas9, which leads mostly to bi-allelic 
HDR editing (Yang et al. 2013; Paquet et al. 2016). Together, the frequency of 
targeted cleavage and HDR mutation was in line with previous literature (C.-C. 









Figure 4.5 | Sequence analyses of each genotype.  
SYNGAP1 sequence alignment of R470A cell lines. DNA sequences of four example 
mutant cell lines were compared with the R470A donor DNA sequence. In 
heterozygous indel Clone1, a perfect match in upstream of the target region is 
followed by a poor alignment and double peaks in the chromatogram. Homozygous 
indel Clone2 shows a perfect match both upstream and downstream of the target 
region. Clone3 has a perfect alignment in the target with an additional insertion. 
Finally, Clone4 shows a complete match with the donor DNA indicating the 
introduction of biallelic HDR mutation. Each chromatogram represents a region of 
sequence highlighted in blue.  
 
Heterozygous indel 
Donor   AGACCGATTCATGGAGCGcGAACACCTgATcTTCgccGAGAACACGCTCGCCACTAAAGCCATAGAAGAGTA 
Clone1  agaccgattcatggagggaaaacatctgattccca--gagaacacactctcccctcaagccctataaaagaa 




Donor   AGACCGATTCATGGAGCGcGAACACCTgATcTTCgccGAGAACACGCTCGCCACTAAAGCCATAGAAGAGTA 
Clone2  agaccga------------------------------gagaacacgctcgccactaaagccatagaagagta 




HDR with indel 
Donor   AGACCGATTCATGGAGCGcGAACACCTgATcTTCgcc---------------------GAGAACACGCTCGC 
Clone3  agaccgattcatggagcgcgaacacctgatcttcgccgagaacacgcttatattccgagagaacacgctcgc 





Donor   AGACCGATTCATGGAGCGcGAACACCTgATcTTCgccGAGAACACGCTCGCCACTAAAGCCATAGAAGAGTA 
Clone4  agaccgattcatggagcgcgaacacctgatcttcgccgagaacacgctcgccactaaagccatagaagagta 




The transfection using the R470A donor has a highest targeting efficiency 
(Figure 4.4A) as well as a highest frequency of HDR mutation (Figure 4.4B). In 
addition, a further examination of the Malachite Green Phosphate assay 
mentioned earlier revealed that the R470A mutation led to a slightly greater 
reduction in the GAP activity than the R470K or R470P mutations (personal 
communication, Dr. Satou Unzai). Therefore, we considered only the R470A 
mutant lines for blastocyst microinjection. Two homozygous cell lines with the 
R470A mutation were further examined by amplifying and sequencing a larger 
region (~ 800 bp) at around the target site using primer SG1-XL-F and SG1-XL-
R. As shown in Figure 4.6, these cell lines were free of unwanted mutations 


















Donor   GAGCACTGTGGCCCCAGGGAAAGCTGGCTTGAGCATGGCTGCCAGCTTGTGGGCGGTGAA 
Hom1    gagcactgtggccccagggaaagctggcttgagcatggctgccagcttgtgggcggtgaa 
        ************************************************************ 
Donor   GAGAGAATAAGATCATGAGGTTGGACTCTGTAGAGGCTGACCCTGGGGTTTTCCTGGGCT 
Hom1    gagagaataagatcatgaggttggactctgtagaggctgaccctggggttttcctgggct 
        ************************************************************ 
 
Donor   CCAGGACTTCCTTTCAGACATGGCCATGTCAGAGGTAGACCGATTCATGGAGCGcGAACA 
Hom1    ccaggacttcctttcagacatggccatgtcagaggtagaccgattcatggagcgcgaaca 
        ************************************************************ 
 
Donor   CCTgATcTTCgccGAGAACACGCTCGCCACTAAAGCCATAGAAGAGTATATGAGACTGAT 
Hom1    cctgatcttcgccgagaacacgctcgccactaaagccatagaagagtatatgagactgat 
        ************************************************************ 
 
Donor   TGGCCAGAAATACCTCAAGGATGCCATTGGTACTTCAGGCCTTCTTCCTGAACCTCCTTG 
Hom1    tggccagaaatacctcaaggatgccattggtacttcaggccttcttcctgaacctccttg 
        ************************************************************ 
 
Donor   TGCCCACCCCACCTCCCCTAAACCTGGCTTCCCAGACCCCATATCCACCTTCCTCAGAGT 
Hom1    tgcccaccccacctcccctaaacctggcttcccagaccccatatccaccttcctcagagt 
        ************************************************************ 
 
Donor   CCCAGGACCCCAGCCTCCAACCATCTGATTCTGCCATTCCTCCAACCCAGGGAGCCCCTG 
Hom1    cccaggaccccagcctccaaccatctgattctgccattcctccaacccagggagcccctg 
        ************************************************************ 
 
Hom2 
Donor  GAGCACTGTGGCCCCAGGGAAAGCTGGCTTGAGCATGGCTGCCAGCTTGTGGGCGGTGAA 
Hom2   gagcactgtggccccagggaaagctggcttgagcatggctgccagcttgtgggcggtgaa 
       ************************************************************ 
 
Donor  GAGAGAATAAGATCATGAGGTTGGACTCTGTAGAGGCTGACCCTGGGGTTTTCCTGGGCT 
Hom2   gagagaataagatcatgaggttggactctgtagaggctgaccctggggttttcctgggct 
       ************************************************************ 
 
Donor  CCAGGACTTCCTTTCAGACATGGCCATGTCAGAGGTAGACCGATTCATGGAGCGcGAACA 
Hom2   ccaggacttcctttcagacatggccatgtcagaggtagaccgattcatggagcgcgaaca 
       ************************************************************ 
 
Donor  CCTgATcTTCgccGAGAACACGCTCGCCACTAAAGCCATAGAAGAGTATATGAGACTGAT 
Hom2   cctgatcttcgccgagaacacgctcgccactaaagccatagaagagtatatgagactgat 
       ************************************************************ 
 
Donor  TGGCCAGAAATACCTCAAGGATGCCATTGGTACTTCAGGCCTTCTTCCTGAACCTCCTTG 
Hom2   tggccagaaatacctcaaggatgccattggtacttcaggccttcttcctgaacctccttg 
       ************************************************************ 
 
Donor  TGCCCACCCCACCTCCCCTAAACCTGGCTTCCCAGACCCCATATCCACCTTCCTCAGAGT 
Hom2   tgcccaccccacctcccctaaacctggcttcccagaccccatatccaccttcctcagagt 
       ************************************************************ 
 
Donor  CCCAGGACCCCAGCCTCCAACCATCTGATTCTGCCATTCCTCCAACCCAGGGAGCCCCTG 
Hom2   cccaggaccccagcctccaaccatctgattctgccattcctccaacccagggagcccctg 
       ************************************************************ 
Figure 4.6 | Extended sequence alignment of the selected R470A cell lines.  
SYNGAP1 sequence alignment of donor (R470A) DNA and the selected cell lines 
(Hom1 and Hom2) showing the exon 9 (highlighted in grey) flanking region. No 
unwanted mutation is found at around the target region. The intended mutation 




4.4 Introduction of specific homozygous and 
heterozygous mutations  
Considering homozygous SYNGAP1 knockout mice die soon after birth, a 
precaution measure needed to be implemented in case the homozygous GAP-
deficiency does the same as the knockout mice, thereby limiting chimaera 
generation derived from homozygous ES cell clones. Therefore, heterozygous 
mutation was introduced in ES cells by a second transfection. However, the 
resulting heterozygous ES cell lines were not used for mouse generation, as the 
initial microinjection of homozygous HDR ES cell lines produced a viable 
germline chimaera. The following paragraph describes generation of a 
heterozygous R470A mutant ES cells.  
As our first transfection yielded only homozygous mutation, a new strategy was 
required to generate heterozygous mutants efficiently. Two methods could be 
applied to introduce heterozygous mutation. The first approach is to design a 
new donor DNA with a longer cut-to-mutation distance (that is a distance 
between Cas9 cleavage site and the desired mutation). There is an inverse 
relationship between a rate of HDR mutation and the mutation’s distance to 
Cas9 cut site (Paquet et al. 2016). In other words, a homozygous mutation can 
be introduced by a sgRNA targeting close to the mutation, while a heterozygous 
mutation is achieved by distant-dependent suboptimal rate of HDR. An 
alternative approach is to use a mix of two donor DNA templates, both contain 
the Cas9-blocking silent mutation, but only one possesses the desired R470A 
mutation (Figure 4.7). The latter approach was chosen for the second 
transfection, since this strategy does not require the construction of a new 
sgRNA plasmid and subsequent functional validation. The equimolar amount of 
R470A and wild-type donor oligos (“mixed donor”) were co-transfected with 
SYNGAP1-targeting pX330 as well as pPGKpuro plasmids. A control experiment 
using only the R470A donor (“single donor”) was performed in parallel.  
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DNA from a total of 335 cell lines (double = 192; single = 143) were screened by 
restriction enzyme digestion. The SYNGAP1-targeting efficiency was 37.5% 
(72/192 cells) for the mixed donor and 32.9% (47/143 cells) for the single 
donor experiment (Figure 4.8A). Sequencing analysis of mutant clones revealed 
that only the mixed donor experiment introduced heterozygous HDR mutation 
in three clones (Figure 4.8B & Figure 4.9). Consistent with the previous 
experiment, there was no heterozygous HDR in the single donor condition. 
Together, the results demonstrate efficient introduction of a specific mono-
allelic mutation using WT and mutant donor templates. Although incorporating 
Cas9-blocking mutations along with pathogenic mutations has been widely used 
to increase HDR accuracy (Doench et al., 2014; Paquet et al., 2016), the 
efficiency of the use of mixed donor templates has not been tested previously. 
Therefore our findings provide the first direct comparison between the use of 
single and mixed donor templates.  Facilitating control experiments at low cost 
can be a key advantage of using ES cell-mediated approach for generation of 
mutant lines (See Table 4.2). 
 
Figure 4.7 | Use of mixed donor templates to introduce heterozygosity. 
Schematic describing introduction of heterozygous mutation using mixed donor templates, 





Figure 4.8 | Comparison between mixed and single donor experiments. 
A. SYNGAP1 targeting efficiency. The number of cell lines is indicated in bars. The 
mixed and single donor experiments show the similar targeting efficiency (37.5% 
and 32.9% respectively).  
B. SYNGAP1 mutation types. Only the mixed donors experiment introduced 




Figure 4.9 | Sequence analysis of a heterozygous HDR cell line.  
Sequencing alignment and DNA chromatogram of a heterozygous HDR cell line (Het 
HDR) from the mixed donor experiment. The R470A mutation was introduced 
together with Cas9-blocking and Sau3AI silent mutations, and all mutations were 










4.5 Mouse generation  
Microinjection and subsequent chimaera generation were performed as 
described in Chapter 3. As mentioned previously, the microinjection of 
homozygous HDR ES cell lines generated a viable germline chimaera (Table 
4.3); thus the heterozygous HDR cell lines were not used any further. F1 agouti 
pups were genotyped using restriction enzyme digestion as explained above 
and a female heterozygous mouse was identified (Figure 4.10A). Subsequent 
sequencing analysis confirmed germline transmission of the R470A mutation 
(Figure 4.10B). Intercross between the heterozygous offspring failed to produce 
homozygous mutants; 76 % (59 mice) were heterozygous, and 24% (19 mice) 
were wildtype indicating the homozygous R470A SynGAP1 mutation causes 
lethality similar to the homozygous SynGAP1 knockout mutation. SynGAP1 
protein expression level of heterozygous R470A mutants was the same as that 
of the wildtype (Figure 4.10, produced by Sarah Lempriere). Together these 
findings support the hypothesis that GAP deficiency is responsible for 
neurological deficits in SynGAP1 knockout mutations in both animal models and 
humans. Further validation of GAP-deficiency in the R470A mutants by 
malachite green phosphate assay needs to be performed.   
 








Pups (F1) Germline 
(F1 Het) 
R470A-Hom16) 60 4 3 0 n/a 
R470A-Hom2 
(12/10/2016) 
58 4 11 1 30 1 
Table 4.3 | Blastocyst injection of homozygous HDR cell lines.  
Two homozygous HDR cell lines (R470A-Hom1 & Hom2) were injected into C57BL/6J 
mouse blastocysts, which were then transferred into recipient mice. An adult male 
chimaera from Hom2 microinjection was mated with C57BL/6J mice and agouti pups 








Figure 4.10 | Germline transmission of R470A mutation.   
A. PCR genotyping of F1 mice. F1 agouti pups were genotyped by restriction enzyme, and 
the presence of a 277 bp cleavage product was considered as a potential germline 
transmission. Note smaller cleavage bands (113 bp and 23 bp) were not visible.   
B. DNA chromatogram of the heterozygous mouse. The target site is highlighted, and the 




Figure 4.111 | Western blot of SynGAP1 mutant mice. 
Representative blot (performed by Sarah Lempriere) of hippocampal homogenates 
from wildtype, heterozygous SynGAP1 knckout and heterozygous SynGAP1 R470A 



























5.1 General methodological discussion 
This study demonstrates the successful generation of novel mouse lines, 
SHANK3 knockout and SYNGAP1 R470A (GAP-deficiency) using ES cells 
modified by the CRISPR/Cas9 system. Our data suggest a high efficiency of 
CRISPR/Cas9-mediated gene deletion (62.5%) and point mutation (4.2%) in ES 
cells. The germline transmission rate was 9.6% for the SHANK3 knockout 
mutation and 2.66 % for SYNGAP1 R470A (Table 5.1).  The combination of 
biallelic genome editing in ES cells and subsequent generation of chimeric 
animals offers a robust tool for efficient gene function analysis in animal models. 
There are several advantages for using ES cell-mediated approach over direct 
zygote injection. First, ES cells modified by the CRISPR/Cas9 system can be 
differentiated into post-mitotic neurons for cellular phenotypic analysis even 
before the generation of animal models. Secondly, while animals born without 
the desired mutations are culled after zygote injection, hundreds of ES cell lines 
can be screened to obtain the precise modification without having to sacrifice 
animal lives. Moreover, mosaicism in the founder generation is highly prevalent 
in zygote injection obfuscating genotyping analysis (Yen et al. 2014; Oliver et al. 
2015). On the other hand, ES cell-derived chimaeric animals require a 
straightforward PCR-based analysis for genotyping. Mosaic animals obtained by 
zygote injection are crossed to generate the heterozygous F1 generation, and 
further breeding is necessary to produce the homozygous F2 generation. 
Therefore, the amount of time for mouse line generation is similar to the ES cell 
mediated approach (about 2-3 months for each generation) (Oji et al. 2016). 
  
Mouse line F1 het/ 
Total F1 mice 
Germline 
transmission rate 
SHANK3-KO 12/125 9.60% 
SYNGAP1-R470A 2/75 2.66% 





5.2 Applications of CRISPR-based technologies   
Recent development of CRISPR-based technologies has extended its application 
to base editing, genome-scale screening, and clinical therapy (Doench et al. 
2014; Zhang et al. 2018a).   
Base editing: Compared to end joining, the HDR-dependent genome editing 
occurs at a low frequency, making CRISPR/Cas9-mediated precise modifications 
less efficient. To make point mutations without using the HDR pathway, 
researchers have developed CRISPR base editors that allow the direct alteration 
of target DNA bases without double-stranded DNA breaks or a donor DNA 
(Komor et al. 2017; Gaudelli et al. 2017; Nishida et al. 2016). The base editors 
are composed of catalytically dead Cas9 (dCas9) fused with a cytidine 
deaminase, and are directed to a target region by a guide RNA. The base editors 
can switch cytosine to uracil near the PAM site, without introducing a DNA 
cleavage (Komor et al. 2016). Uracil is then changed to thymine by DNA 
replication or repair facilitating C to T conversion or G to A on the opposite 
strand. The base editing results in a higher editing efficiency than HDR and 
fewer off-target effects than Cas9-mediated approach (Kim et al. 2017; Rees et 
al. 2017). Novel adenine base editors can now allow previously unavailable A to 
G (or T to C) conversion (Gaudelli et al. 2017). The ability to introduce or 
remove a single-nucleotide variation (SNV) in target genes indicates the 
potential of the CRISPR base editing in therapeutic applications. Targeting 
flexibility and specificity of the CRISPR base editing continues to be improved 
and assessed.  
Genome-wide screening: The CRISPR technology has been repurposed to 
enable a large-scale genetic screening to identify specific genetic elements 
influencing a phenotype of interest. Traditionally, genetic screening approaches 
have relied on DNA mutagenesis (by chemical mutagen, radiation, or insertion 
of mobile genetic element) or RNAi for manipulation of transcript levels. 
However, screening using DNA mutagenesis requires laborious mapping of the 
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mutation sites (Sanjana 2017). RNAi-mediated screening is also limited by 
incomplete knockdown and high off-target effects (Jackson & Linsley 2010; 
Jackson et al. 2003). Recently, the CRISPR system has been adapted for genome-
wide screening by combining Cas9 with pooled guide RNA libraries and next-
generation sequencing. The pooled CRISPR screen has been used in loss-of-
function assays to identify cancer drug targets (Shi et al. 2015), bacterial toxin 
resistance (Koike-Yusa et al. 2014), mitochondrial metabolism (Birsoy et al. 
2015), and gene regulatory networks in immune cells (Parnas et al. 2015; 
Schmid-Burgk et al. 2016). In addition, dCas9-based screening has facilitated 
both genome-wide gain-of-function and loss-of-function screenings using arrays 
of transcriptional activator or repressor domains in combination with guide 
RNA libraries targeting gene promoters (Klann et al. 2017). Further 
developments in CRISPR-based RNA editing (Cox et al. 2017) and base editing 
(Gaudelli et al. 2017) will broaden the applicability of the CRISPR screen. Given 
the rapid pace of CRISPR-based technology development, the CRISPR pooled 
screening will deepen our understanding of genomic and epigenomic elements 
in both health and disease.  
Clinical therapy: The CRISPR-based technology has shown potential in clinical 
therapy mainly involving immune cells and stem cells. The development of 
CRISPR technologies has enabled various ex vivo genetic engineering in human 
T cells to improve safety and efficiency of T cell-based immunotherapy (Zhang 
et al. 2017). Apart from T cells, genetic modification of induced pluripotent stem 
cells (iPSCs) has made progress in the field of neurodegenerative diseases 
including Alzheimer’s disease (Pires et al. 2016) and Parkinson’s disease 
(Heman-Ackah et al. 2017). The safety and efficiency of the iPSCs transplant as 
cell therapy remain to be validated. Although still in its infancy, CRISPR-based 
clinical therapy will likely offer the opportunity to develop novel cell therapies 
as further research will continue in order to augment gene targeting accuracy 




Limitations: Given that off-target effects of the CRISPR system can be largely 
avoidable (see Chapter 1), the main technical challenge of CRISPR-based 
technologies may be Cas9 delivery.  Initially, the CRISPR system relied on 
delivering plasmid or viral vectors encoding sgRNA and Cas9. However, this 
method suffers from limitations regarding plasmid transfection toxicity or 
immunity against viral vectors respectively (Kay 2011). More recently, the 
delivery of CRISPR components in a format of Cas9/sgRNA ribonucleoprotein 
complex has been shown to have several advantages because of lower off-target 
effects and higher nuclease activity compared to plasmid transfection 
(Kouranova et al. 2016; Kim et al. 2014; Staahl et al. 2017). The in vivo delivery, 
however, has to overcome several challenges including RNA-sensing innate 
immune responses leading to cytotoxicity (Kim et al. 2018), and inability for 
global delivery to the target cells, tissues or organs (Zhang et al. 2018b). For the 
efficient in vivo genome editing, further studies on delivery methods, such as 
nanoparticles (Lee et al. 2017) are necessary.   
 
5.3 SHANK3 knockout mouse model 
We created a novel SHANK3 knockout mouse line using the CRISPR/Cas9 
technology leveraging the premature termination pathway. This is different 
from the existing mouse models of SHANK3 deficiency which have been 
generated from traditional gene targeting methods relying on homologous 
recombination (Bozdagi et al. 2010; Peça et al. 2011; Wang et al. 2011; Jaramillo 
et al. 2016). Although each of the existing lines targeted different exons (see  
Figure 3.186), all of these mutations disrupt the expression of the full-length 
SHANK3 (isoform 1), similar to the novel SHANK3 line; therefore the novel line 
is expected to have the similar phenotypes.   
SHANK3 knockout mice display autism-related behaviours to different degrees 
(Bozdagi et al. 2010; Peça et al. 2011; Wang et al. 2011; Jaramillo et al. 2016). It 
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is worth testing, therefore, whether (and to what extent) our SHANK3 mice 
recapitulate core autism traits (i.e. social interaction deficits and repetitive 
behaviours). Autism-like phenotypes can be measured by a number of 
behavioural tests, for example, the three-chamber sociality test, ultrasonic 
vocalisation to examine communication patterns, and self-grooming for 
measuring repetitive behaviours (Wang et al., 2011). A next question is how to 
rescue the autism-associated behavioural deficits. Several lines of evidence 
suggest pharmacological interventions can reverse the deficits in animals by 
targeting actin regulators (Duffney et al. 2015), mGluR5 (Vicidomini et al. 2016) 
or histone deacetylase (HDAC) (Qin et al. 2018). Future studies will determine 
whether these pharmacological experiments would be reproducible and 
clinically applicable.  
The behavioural abnormalities observed in SHANK3 deficiency mice have been 
attributed to the dysfunction of glutamatergic synapses (Bozdagi et al. 2010; 
Peça et al. 2011; Wang et al. 2011; Jaramillo et al. 2016). In particular, the 
dysregulation of NMDARs is strongly related to social interaction deficits 
(Duffney et al. 2015; Qin et al. 2018). Previous studies show NMDAR 
hypofunction induced by SHANK3 deficiency is caused by the loss of synaptic 
trafficking of NMDARs (Duffney et al. 2015; Duffney et al. 2013). One critical 
issue is the molecular mechanism behind the loss of synaptic delivery of 
NMDARs.  
MAGUKs, such as PSD95 and SAP102, are scaffolding proteins that anchor and 
traffic NMDARs to the synapse (Ryan & Grant 2009; Zhu et al. 2016), and 
physically interact with SHANK3 (Naisbitt et al. 1999; O’Connor et al. 2014). We 
therefore hypothesise the alteration in synaptic distributions of MAGUKs would 
be observed in mice lacking SHANK3. To test this hypothesis, an additional 
SHANK3 knockout mouse line was generated which expresses florescent tags in 
endogenous PSD95 and SAP102, as described in Chapter 3. PSD95- and SAP102-
positive synapses will be directly visualised by high-resolution microscopy to 
investigate the morphology, density, intensity and size of MAGUK puncta in 
various brain regions. Supporting the hypothesis, loss of SHANK3 in mouse 
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models reduces spine density (Peça et al. 2011; Wang et al. 2011), and 
expression levels of multiple synaptic proteins (Peça et al. 2011; Wang et al. 
2011; Bozdagi et al. 2010; Yang et al. 2012). Thus it is likely that changes in 
brain-wide synaptic maps will be observed from our SHANK3 knockout mouse 
line.  Examining the effect of SHANK3 deficiency in the MAGUK synapse maps 
will provide crucial information on the molecular architecture of PSD proteins, 
and give an insight into the pathophysiology of the monogenic cause of autism.  
 
5.4 SYNGAP1 GAP-deficient mouse model 
We introduced the SYNGAP1-R470A point mutation into the mouse genome for 
the first time to investigate the role of GAP function in the pathophysiology of 
SYNGAP1 haploinsufficiency. A planned experiment is to characterise 
heterozygous SYNGAP1 GAP-deficient mice using a number of approaches for 
phenotypic analyses including behavioural tests, electrophysiology, and 
biochemistry. The phenotypes of the GAP-deficiency will be compared with the 
existing SYNGAP1 heterozygous null mutation mice to see whether the GAP-
deficiency mirrors SYNGAP1 loss-of-function. If that is the case, this indicates 
human endophenotypes such as learning impairments and social deficits are 
largely caused by loss of GAP function, and can be rescued by a pharmacological 
therapy. The effective therapeutic can be developed by a simple compound 
library screening to identify a compound which enhances the GAP activity. Such 
pharmacological investigations will not only explore the therapeutic potentials 
of GAP enhancers but also provide a new insight into molecular mechanisms of 
PSD protein interactions involving SYNGAP1. 
Alternatively, it is also possible that the phenotypic profile of the GAP-deficiency 
is significantly different from the knockout phenotypes. For example, if the GAP-
deficiency has a significantly larger effect size than the knockout for the 
phenotype, this may be due to the dominant negative effect of the SYNGAP1 
point mutation. In other words, the R470A mutant protein adversely affects the 
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normal functions of the wild-type protein. On the other hand, in case the GAP-
deficiency has a less severe phenotype, this may indicate the other functions 
such as scaffolding play an important role in the pathophysiology of SYNGAP1 
haploinsufficiency. Further experiment on mutations in protein-protein binding 
domains of SYNGAP1, such as the PDZ ligand domain (See Figure 1.6), will 
determine whether the scaffolding function is as crucial as the GAP function.  
Another possibility is that the phenotypes of the GAP-deficient mice are not 
significantly different from those of the wild-type mice. This may suggest that 
the GAP activity of SYNGAP1 is functionally redundant, and other GAP proteins 
or mechanisms that do not involve SYNGAP1 protein can regulate the 
appropriate levels of GTPase activation in cells. Taken together, further 
understanding of structural and functional roles of SYNGAP1 will deepen our 
understanding of the molecular organisation of NMDAR complexes and its 
associated pathways.   
 
5.5 A common pathway of SHANK3 and SYNGAP1     
Although many NMDAR-interacting proteins have been found in NMDAR 
complexes (Fan et al. 2014; Grant & O’Dell 2001), protein-protein interactions 
have not been investigated in detail. The current study has laid the foundations 
of a robust and efficient in vivo investigation of such protein interactions in 
NMDAR complexes. In particular, we focused our attention on two NMDAR-
interacting proteins SHANK3 and SYNGAP1. Because of the commonalities 
between the two proteins as described previously, we hypothesised these two 
proteins would be identified in NMDAR complexes, and they are involved in a 
common molecular pathway. Analyses of the novel mutant mice will not only 
validate these protein interactions in vivo, but also determine whether SYNGAP1 
and SHANK3 act as a direct downstream effector of the NMDA receptor 
signalling, and if these proteins regulate the same downstream signalling 
pathway which may be targeted therapeutically. As molecular mechanisms, 
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cellular events, and alterations in brain connectivity are conserved among mice 
and humans (Nithianantharajah et al. 2013), further research on this topic may 
open new avenues for diagnosis and therapeutic discoveries.  
 
Figure 5.1 | Molecular pathway involving SHANK3 and SYNGAP1. 
Diagram illustrating Ras-ERK dependent protein synthesis as a common molecular 
pathway of SHANK3 and SYNGAP1. NMDAR activation allows Ca2+ influx which 
enables CaMKII to phosphorylate many postsynaptic proteins including SYNGAP1, 
SHANK3 and MAGUKs. Phosphorylated SYNGAP1 inhibits Ras, thereby 
downregulating ERK-dependent protein synthesis. CaMKII may also directly 
influence ERK. Altered protein synthesis will have an impact on trafficking of 
receptor proteins such as NMDARs and AMPARs. 
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One potential common pathway of SHANK3 and SYNGAP1 is the Ras-ERK signal 
transduction cascade (Figure 5.1). Upon activation of NMDARs, Ca2+ flows 
through the receptors activating CaMKII (Kennedy 2016). The active CaMKII 
phosphorylates SYNGAP1 which, in turn, decreases the activity of Rap and Ras, 
leading to a rapid reduction in AMPAR endocytosis via the regulation of the Ras-
ERK pathway (Walkup et al. 2016). SHANK3 is also phosphorylated by CaMKII, 
and is an abundant component of CaMKII multiprotein complexes at the PSD 
(Baucum et al. 2015). Supporting the potential involvement of CaMKII in the 
physiological regulation of SYNGAP1 and SHANK3, CaMKII mutations were 
identified in ASDs (Chiocchetti et al. 2018; Iossifov et al. 2014). Thus, it is 
possible that CaMKII, SHANK3 and SYNGAP1 converge on the Ras-ERK 
signalling. Consistent with this hypothesis, pathway and network analyses of 
ASD-related genes show calcium signalling and the Ras-ERK pathway are the 
most enriched pathways indicating the process involving calcium-Ras-ERK is a 
major contributor to the pathophysiology of ASDs (Wen et al. 2016). Given 
perturbed proteostasis has been associated with ASDs (Louros & Osterweil 
2016), it is conceivable that a disrupted Ras-ERK pathway is linked to an 
imbalance in protein homeostasis in synapses. Further examination of the 
interplay of SHANK3 and SYNGAP1 in the Ras-ERK pathway will facilitate the 
discovery of novel drug targets for ASDs and other NMDAR complexes-related 
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